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ABSTRACT 
 
 
BHAWANA BARIAR. Topoisomerase II inhibitors induce an illegitimate genome 
rearrangement common in infant leukemia. (Under the direction of DR. CHRISTINE 
RICHARDSON) 
 
 
 Infant acute leukemias account for ~30% of all malignancy seen in childhood 
across the Western world. They are aggressive and characterized by rapid onset shortly 
after birth. The majority of these have rearrangements involving the MLL (mixed lineage 
leukemia) gene. Although MLL fusion to more than 75 genes have been identified, AF9 is 
one of its most common translocation partners. Since MLL breakpoint sequences 
associated with infant acute leukemia are similar to those in secondary AML following 
exposure to the topoisomerase II (topo II) poison etoposide, it has been hypothesized that 
exposure during pregnancy to biochemically similar compounds may promote infant 
acute leukemia. Some studies have shown an epidemiological link between bioflavonoid 
intake and increased incidence of MLL-rearranged infant leukemias. Hundreds of 
unregulated nutritional supplements are widely available and perceived to prevent 
cardiovascular disease, inflammation and cancer. However, their potential to promote 
leukemic translocations should be determined. My goal was to test the hypotheses that 1) 
MLL and AF9 breakpoint cluster regions (bcrs) undergo double strand breaks (DSBs), 
and are highly recombinogenic independent of chromosomal context, and in the absence 
of a leukemic fusion protein; and 2) a number of topoisomerase II inhibitors have the 
potential to promote these translocations analogous to those observed in infant leukemia. 
To test these hypotheses, I developed transgenic reporter cell lines such that a 
translocation between MLL and AF9 bcrs results in a full-length GFP transcript and 
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quantifiable green fluorescence. I show here that topo II inhibitors such as the 
bioflavonoids genistein, quercetin, luteolin and myricetin lead to MLL-AF9 bcr 
translocations, genistein and quercetin being the most potent promoters. Notably, 
benzoquinone which is associated with non-MLL-rearranged leukemias do not promote 
MLL-AF9 translocations even at a high dose. I demonstrate here the sensitivity of the 
MLL and AF9 bcrs to topo II poisons and bioflavonoids independent of their normal 
chromatin context and independent of the formation of a leukemic fusion protein. In 
addition, this reporter gene system allows for rapid and reproducible screening of 
hundreds of compounds that may have the potential to promote leukemogenic 
translocations. 
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CHAPTER 1: INTRODUCTION 
 
 
 In this thesis I have tested the hypotheses that 1) MLL and AF9 bcrs undergo 
DSBs, and are highly recombinogenic independent of chromosomal context, and in the 
absence of a leukemic fusion protein; and 2) a number of topo II inhibitors have the 
potential to promote these translocations analogous to those observed in infant leukemia. 
I demonstrate here the sensitivity of the MLL and AF9 bcrs to topo II poisons and 
bioflavonoids independent of their normal chromatin context and independent of the 
formation of a leukemic fusion protein. 
 Chapter 3 describes the establishment of a reporter gene model system to screen 
for the frequency of MLL-AF9 translocation events. Chapter 4 describes the 
quantification of GFP+ colonies after endonuclease ISceI expression which induces 
directed DNA breaks in reporter cell lines. Chapter 5 describes the quantification of 
GFP+ colonies after treating the reporter cell lines with varying doses of different topo II 
inhibitors including the chemotherapeutic drug etoposide and different bioflavonoid 
compounds which are found in our diet and are also used as nutritional supplements. 
1.1 Hematopoiesis 
Hematopoiesis is the process of formation of blood cells (Figure 1). All mature 
and differentiated blood cells are derived from hematopoietic stem cells (HSCs).  
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Figure 1: The process of hematopoiesis 
 
 
Hematopoiesis is characterized by the constant self-renewal of a small stem cell 
pool, and expansion and differentiation into an array of progressively restricted myeloid 
and lymphoid cell types. Hematopoietic stem cells (HSC) are a rare cell population 
among hematopoietic progenitors present in the bone marrow, characterized by 
CD34+/CD38- markers and are distinguished by self-renewal, long-term multi-lineage 
repopulating potential, and ability to reconstitute hematopoiesis both in vivo and in vitro 
(Hao, Shah et al. 1995, Hao, Thiemann et al. 1996). Leukemic HSCs display properties 
similar to normal HSC including CD34+ expression, self-renewal and potential for 
propagation of a leukemic clone (Lapidot, Sirard et al. 1994, Sutherland, Blair et al. 1996, 
Bonnet and Dick 1997, Jamieson, Weissman et al. 2004). 
1.2 Childhood and infant leukemia 
Hematopoietic malignancies include leukemia and lymphoma. Leukemia is a type 
of cancer of the blood or bone marrow characterized by an abnormal increase of 
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immature white blood cells. Lymphoma is a type of blood cancer that occurs when B or T 
lymphocytes that form a part of the immune system undergo uncontrolled division. 
Lymphoma may develop in many parts of the body, including the lymph nodes, spleen, 
bone marrow, blood or other organs, and eventually form a tumorous mass of cells. These 
tumors may grow and invade the space of surrounding tissues and organs.  
Infant acute leukemias account for ~30% of all malignancy seen in childhood 
across the Western world. Leukemias are the most common cancer that affect children 
since 25% to 35% of all childhood cancers are leukemias (Lightfoot and Roman 2004). 
Infant leukemias which occur at less than one year of age, grow rapidly, are aggressively 
invasive and are characterized by rapid onset shortly after birth. The major morphological 
types of childhood leukemia have been documented as acute lymphoblastic leukemia 
(ALL) and acute myeloblastic leukemia (AML). ALL is the more predominant form of 
infant leukemia, while AML accounts for around 15 – 17% of the cases. ALL is the most 
common form of childhood cancers. Youngest infants have the worst outcome leading to 
death. These leukemias are frequently characterized by genetic alterations which include 
chromosomal translocations and other rearrangements such as deletions (Felix and Lange 
1999). The high frequency of recurring chromosomal rearrangements identified in 
leukemia and lymphoma suggests they result from an error in normal gene 
rearrangements of the hematopoietic developmental program. 
1.3 MLL gene rearrangements and leukemia 
Approximately 85% of infant ALL cases, and 50% of infant AML cases involve 
rearrangements of the MLL 11q23 gene (Cimino, Lo Coco et al. 1993, Ford, Ridge et al. 
1993, Sorensen, Chen et al. 1994, Gale, Ford et al. 1997, Dimartino and Cleary 1999, 
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Felix and Lange 1999, Lightfoot and Roman 2004). 11q23 rearrangements are associated 
with a poor outcome (Chen, Sorensen et al. 1993, Taki, Ida et al. 1996, Reaman, Sposto 
et al. 1999). MLL is a transcriptional regulatory factor expressed in hematopoietic cells, 
and aberrant expression of MLL in these cells due to a translocation may give rise to 
leukemia.  
A diverse group of karyotypic abnormalities involving the rearrangement of the 
MLL gene are found in these hematological malignancies. More than 75 fusion partner 
genes for MLL have been identified. AF9 gene is one of its most common translocation 
partners (Dimartino and Cleary 1999, Ayton and Cleary 2001, Lightfoot and Roman 
2004). In addition to reciprocal balanced translocations to partner genes, 11q23 
rearrangements include deletions, duplications or amplifications (Bernard and Berger 
1995, Rowley 1999, Ayton and Cleary 2001). There is evidence to suggest that these 
translocations may initially form in utero (Ford, Ridge et al. 1993, Taki, Ida et al. 1996, 
Gale, Ford et al. 1997, Megonigal, Rappaport et al. 1998, Wiemels, Cazzaniga et al. 
1999, Wiemels, Xiao et al. 2002, Felix, Kolaris et al. 2006). 
The human MLL gene is found on locus 11q23 and its translocations are typically 
found in mixed lineage leukemia as discussed earlier. Its normal function in the cells and 
the aberrant activities of MLL fusion proteins are well known and briefly described here.  
Rearrangement of the MLL locus can be sufficient to promote transformation of 
normal blood progenitors to leukemia stem cells (Cozzio, Passegue et al. 2003, Hotfilder, 
Rottgers et al. 2005, Jordan 2006, Kong, Sham et al. 2006) 
The MLL (mixed lineage leukemia) gene is a homolog of a known Drosophila 
gene named trithorax (Trx) (Slany 2009). Like Trx, MLL also regulates the expression of 
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Hox genes which play an important role in development and pattern formation in the 
embryo. The MLL protein contains a highly conserved SET domain (an acronym for 
Suppressor of variegation, Enhancer of zeste, trithorax) at the C-terminus as the site of a 
histone methyltransferase activity that specifically methylates histone H3 at lysine 4. 
MLL is post-translationally processed by proteolytic cleavage where it is cut by an 
aspartic protease into an N-terminal 320 kDa fragment and a C-terminal 180 kDa moiety.  
The C-terminal subunit associates with proteins that help in preparing the 
chromatin for efficient transcription. The histone H4 lysine 16 specific acetyltransferase 
MOF loosens up the chromatin. The WDR5 protein recognizes the H3K4 methyl-mark 
introduced by MLL and ensures the processivity of histone modification. The proteins 
RBBP5 and ASH2L appear to be necessary for efficient methyltransferase activity.  
The N-terminal domain MLL
N 
is essential for correct targeting of the MLL 
complex. It interacts with the proteins menin (the product of the tumor suppressor gene 
multiple endocrine neoplasia) and LEDGF (lens epithelium derived growth factor). In 
addition, MLL codes for several AT-hooks, which is a motif that binds to minor groove 
DNA, and preferentially recognizes DNA with distortions like bends or kinks. MLL also 
has a CxxC domain which binds specifically to unmethylated CpG dinucleotides. The N-
terminal subunit also has a plant homeodomain (PHD). These domains of the MLL 
complex coordinate three major mechanisms of chromatin modification: methylation, 
acetylation and nucleosome remodeling. 
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Figure 2: The MLL complex. After post-transcriptional proteolytic processing amino-
terminal and carboxy-terminal portions of MLL are incorporated in a macromolecular 
complex with histone methyltransferase and histone acetyltransferase function. 
Functional domains in MLL are indicated in yellow. AT = AT-hooks, a DNA binding 
domain, CxxC = motif recognizing unmethylated CpG dinucleotides, PHD = plant 
homeodomain, SET = histone methyltransferase active site. 
 
 
1.4 MLL gene structure 
 The MLL gene, also known as the All-1 or HRX is present at chromosomal 
position 11q23 (Stanulla, Wang et al. 1997). The gene spans a length of ~120 kb, and is a 
major fusion partner of reciprocal chromosomal translocations involved in acute de novo 
and therapy-related leukemias affecting hematopoietic cells of lymphoid and myeloid 
lineages (Daser and Rabbitts 2005). The MLL protein is 500kD in size, is involved in 
transcriptional regulation and contains regions of high homology to the Drosophila 
trithorax protein. Virtually all MLL translocation breakpoints in patient samples occur in 
an 8.3 kb BamHI fragment, the bcr (Strissel, Strick et al. 2000) present between exons 8 
to 14. An in vivo topo II cleavage site and a DNase I hypersensitive (HS) site colocalize 
within a high affinity scaffold associated region (SAR). Recent research has also shown 
the presence of two palindromic sequences, each 10 bp in size, ~101 bp apart and present 
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towards the 3’ end of the bcr (Le, Singh et al. 2009) . A high affinity topo II binding site 
has shown to be present at the geometric midpoint of this palindromic DNA(Le, Singh et 
al. 2009). This specific region of MLL present at the intron 11 and exon 12 borders is also 
a DNase I hypersentitivity target(Le, Singh et al. 2009). It has been postulated that these 
in cis elements promote the cleavage and eventual rearrangements that initiate within the 
MLL bcr. In addition, the MLL bcr is AT rich and contains numerous Alu elements that 
may promote open chromatin structure and recombination events during repair of DSBs 
or stabilized topo II cleavage sites. 
  
 
Figure 3: MLL bcr with the exons indicated. The bcr is within an 8.3 kb BamHI (B) 
fragment and is frequently involved in translocations. The arrow at exon 12 shows the 
presence of a strong topo II cleavage site (Strissel, Strick et al. 2000). 
 
 
1.5 Impact of 11q23 translocations and MLL fusion proteins 
As mentioned earlier in the introduction, MLL has been found in 73 different 
translocations and 54 partner genes have been cloned so far. An aberrant non-
homologous end joining (NHEJ) process most likely results in these illegitimate 
translocations. All MLL fusion proteins share a common structure where the fusion 
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partner is fused in frame to MLL
N 
after the CxxC domain but excluding the PHD fingers. 
Studies have suggested that the leukemogenic function of these MLL fusion proteins can 
be activated in four different ways (Slany 2009): 
1. Transcriptional elongation and histone methylation (fusion partners ENL, AF9, 
AF4, ELL, and AF10)  
There is a protein complex known as EAP (ENL associated protein complex) 
where ENL is not only linked with all members of the AF4 protein family that occur as 
MLL fusion partners, but also with positive transcription elongation factor b (pTEFb) and 
the histone methyltransferase DOT1L. pTEFb phosphorylates the carboxy-terminal 
repeat domain of RNA polymerase II, and this activity is essential for efficient 
transcriptional elongation. DOT1L methylates H3K79, which also happens during 
transcriptional elongation. 
AF10, ENL, ELL fusion proteins with MLL have all been shown to interact or 
participate in these two processes of histone methylation and transcription elongation. 
Thus these common fusion partners with clinical importance participate in the same 
biological process for control of transcriptional elongation. MLL fusions might recruit 
EAP to genomic loci to induce ectopic target gene expression.  
2. Histone acetylation (fusion partners CBP and p300) 
A few cases of therapy induced secondary leukemia present MLL fusions with the 
histone acetyl-transferases CREB binding protein (CBP) and the related p300. The 
bromo- and histoneacetyltransferase domains of CBP are necessary and sufficient for the 
oncogenic function of the respective fusion proteins. The permanent HAT activity results 
in a hyperacetylation of chromatin and activated transcription. 
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3. MLL-EEN arginine specific histone methylation 
The EEN fusion partner was cloned from a single case of mixed lineage leukemia. 
EEN was demonstrated to be bound to the arginine methyltransferase PRMT1 through 
the adaptor protein SAM68. PRMT1 is an arginine specific methyltransferase that also 
methylates histone H4 at arginine 3. This modification is correlated with an increased 
histone acetylation. This could lead to an activation of transcription in the same way as 
mentioned for CBP or p300 above.  
4. Cytoplasmic fusion partners and dimerization 
These fusions are found preferentially in older patients and seem to be more 
weakly transforming as compared to fusions with nuclear proteins. MLL fusions with the 
cytoplasmic proteins GAS7, AF1p and AF6 have been studied and the minimally 
necessary contributions of the respective fusion partner have been localized to coiled-
coiled dimerization domain. All MLL fusion proteins are imported to the nucleus because 
of the strong nuclear import signals in MLL. This leads to aberrant protein-protein 
interactions of the fusions partners and aberrant activation of pathways.  
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Figure 4: Molecular pathways leading to oncogenic activity of MLL fusion proteins. 
MLL fusions are aberrant transcription factors that activate gene expression. Four 
different mechanisms have been suggested as to how fusion partners might induce 
transcriptional activation. (A) The most frequent fusion partners of the ENL and AF4 
family are members of the EAP complex that combines histone H3K79 methyltransferase 
activity catalyzed by DOT1L with transcriptional elongation stimulation by pTEFb 
(positive transcription elongation factor b, a dimer of CDK9 and a cyclinT) that 
phosphorylates the C-terminal repeat domain of RNA polymerase II. It is speculated that 
MLL fusion proteins aberrantly recruit this complex to target chromatin. (B) Active 
histone acetyltransferases are fused to MLL in the MLL-CBP and MLL-p300 proteins. 
(C) MLL-EEN indirectly recruits the histone H4R3 arginine methyltransferase through 
binding of the adaptor SAM68. (D) Dimerization of MLL via coiled-coiled or other 
dimerization domains supplied by the fusion partner activates target genes by unknown 
mechanisms. 
 
 
These are the different mechanisms of activation of MLL fusion proteins. 
Deregulation of Hox genes is the most important factor for MLL fusion induced 
leukemogenesis. HOX proteins, especially HOXA9, and its dimerization partner MEIS1, 
are the major hematopoietic proteins that are overexpressed in a wide variety of different 
leukemias. HOX expression is high in hematopoietic stem cells and early precursor cells 
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and needs to be down-regulated for normal hematopoietic differentiation and maturation. 
Therefore, a continuous ectopic HOX expression blocks normal differentiation and 
creates a rapidly proliferating pre-leukemic precursor pool which can undergo secondary 
mutations to lead to acute leukemia.  
1.6 MLL and AF9 translocations 
AF9 is one of the most common translocation partners for MLL (Dimartino and 
Cleary 1999, Ayton and Cleary 2001, Lightfoot and Roman 2004). Sequence analysis of 
MLL-AF9 translocation breakpoints from patient-derived tumor samples has shown small 
deletions and insertions, as well as larger deletions, duplications, and more complex 
rearrangements (Gu, Alder et al. 1994, Strissel, Strick et al. 1998, Whitmarsh, Saginario 
et al. 2003).  
1.7 AF9 gene structure 
 The AF9 gene, also called LTG9 or MLLT3, spans >100kb and is present at 
chromosomal position 9p22. AF9 is a common fusion partner of the MLL gene (Strissel, 
Strick et al. 2000, Alonso, Longo et al. 2008). The MLL-AF9 fusion gene is associated 
with AML, ALL as well as with t-AML (Strissel, Strick et al. 2000). The translocation, 
denoted by t(9;11)(p22;q23), is the third most frequently reported abnormality in infant 
ALL cases (Alonso, Longo et al. 2008). In vitro and in vivo studies have shown that the 
MLL-AF9 fusion gene plays an important role in stem cell development and 
leukemogenesis (Corral, Lavenir et al. 1996, Dobson, Warren et al. 1999). Leukemias 
that carry the MLL-AF9 fusion are clinically aggressive, difficult to treat, often resistant 
to traditional therapy regimens with the intensive therapies generally being toxic, and 
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have poor prognosis and survival rates (Elliott and Jasin 2002). This is especially true 
with infant leukemias.  
 At present, the specific function of the AF9 gene is unknown. However, the 
mouse homolog of human AF9 is suggested to have a role in embryo patterning via 
Hoxd4 gene expression (Collins, Appert et al. 2002, Daser and Rabbitts 2005). The AF9 
gene has two bcr regions identified within BamHI sites; bcr1 within intron 4 and bcr2 
spanning introns 7 and 8 (Strissel, Strick et al. 2000). A topo II cleavage site and a 
DNaseI hypersensitivity site are located within intron 7 in the bcr2. Two SARs border 
both breakpoint regions (Strissel, Strick et al. 2000). These breakpoint and topo II 
cleavage sites were identified from clinical samples of t-AML, infant AML and adult 
ALL patients (Negrini, Felix et al. 1993). 
  
 
Figure 5: Human AF9 gene with the bcrs shown. The numbered bars on the map indicate 
the position of exons. BamHI sites (B) and the SARs are represented. The arrow indicates 
the location of the topo II cleavage site. 
 
 
1.8 Topo II poisons and chemotherapeutic agents lead to MLL-AF9 translocations  
I am interested in investigating the possible causes that lead to MLL-AF9 
translocations. One of the numerous possible factors that can lead to these translocations 
are topoisomerase II (topo II) poisons. DNA topoisomerases are essential cellular 
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enzymes that cause topological changes in the DNA for processes like replication, 
transcription etc. They are the targets of many important anticancer and antibacterial 
drugs. Topo II is targeted and inhibited by the widely used anticancer agents etoposide, 
doxorubicin, daunorubicin and mitoxantrone (Pommier, Leo et al. 2010). These topo II 
poisons target the DNA-protein complex. These compounds inhibit the religation of the 
transient DSBs made by topo II and this can lead to chromosomal abnormalities. The 
induction of DSBs is associated with chromosomal rearrangements, especially of the 
MLL gene which is frequently rearranged in chemotherapy-related leukemia. These 
breakpoints and rearrangements are similar to those that are found in infant leukemias 
due to exposure to topo II inhibitors such as these chemotherapeutic drugs. 
The widely used anticancer drug etoposide has been reported to initiate MLL 
rearrangements in primitive hematopoietic stem cells and in human fetal hematopoietic 
stem cells in several studies (Libura, Slater et al. 2005, Moneypenny, Shao et al. 2006, 
Sung, Libura et al. 2006, Libura, Ward et al. 2008). Etoposide induces chimeric MLL 
gene fusions in mouse embryonic stem cells (Blanco, Edick et al. 2004). Other anticancer 
drugs including etoposide, teniposide, anthracyclines and dactinomycin are associated 
with MLL rearrangements due to topo II inhibition and enhanced DNA cleavage leading 
to defective DNA repair. Thus, these potent inhibitors induce topo II to cause 
chromosomal breakage and the repair of these breaks leads to translocations (Felix 2001). 
1.9 Do other topo II inhibitors promote MLL-AF9 translocations? 
Studies have indicated that certain dietary compounds may have the potential to 
cause illegitimate DNA repair which can have important consequences for cancer 
development and other diseases. Bioflavonoids comprise a diverse group of polyphenolic 
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compounds. The most common sources of these bioflavonoids are fruits, vegetables, soy, 
tea, coffee and wine (Ross 2000). Due to their antioxidant capacity, they are used for 
their presumed health benefits such as protection against cardiovascular diseases, cancer 
and inflammation. Flavonoid supplements are available worldwide over-the-counter in 
pharmacies and drugstores. However, they have been shown to potently suppress the 
activity of the essential cellular enzyme topo II.  
High levels of genistein in maternal diet during pregnancy have been associated 
with the development of infant leukemia. Evidence suggests that topo II is implicated in 
genistein-induced infant leukemia. It has been reported that genistein induces DNA 
sequence rearrangements that are mediated by topo IIβ and the proteasome (Azarova, Lin 
et al. 2010). This study was carried out in vitro using purified recombinant human topo II 
enzymes as well as in cultured mouse myeloid progenitor cells (32Dc13) and Top2β 
knockout mouse embryonic fibroblasts (MEFs). It was shown that 100 µM genistein 
efficiently induced topo II-DNA cleavage complexes in both the systems and it was 
suggested that these complexes are processed by proteasome which led to chromosome 
rearrangements. This is evidence that both topoII and proteasome play a major role in 
genistein-induced infant leukemia.  
Exposure of the developing fetus to such compounds during pregnancy increases 
the risk of infant leukemia. The first study that dietary bioflavonoids have the potential to 
induce cleavage in the MLL gene which could lead to infant leukemia tested 20 different 
bioflavonoids (Strick, Strissel et al. 2000). MLL cleavage was shown to be induced both 
in vivo in primary human progenitor hematopoietic cells from healthy newborns and 
adults as well as in vitro in hematopoietic progenitor cell lines (BV173 and K562). These 
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compounds caused inhibition of topo II enzyme in different doses. These results were the 
first to suggest that maternal ingestion of these compounds could lead to infant leukemia 
by inducing chromosome translocations.  
Importantly, a study has shown that synthetic flavonoids are able to cross the 
placenta in the rat and are found in all fetal tissues (17% of the initial dose) including the 
fetal brain (Schroder-van der Elst, van der Heide et al. 1998). A synthetic bioflavonoid 
EMD-49209 was radioactively labeled and its maternal and fetal distribution was 
investigated in this study 1-24 h after intravenous injection in Wistar rats that were 20 
days pregnant.  
Genistein has been reported to induce chromosome aberrations similar to those 
found in infant leukemia (Abe 1999). Genistein is abundant in soybeans and is a potent 
topo II inhibitor. Cultured human lymphocytes treated with 50 µM genistein display 
chromosome abnormalities in metaphase karyotypic analyses. Topo II inhibition by 
different bioflavonoids was investigated in an in vitro plasmid DNA cleavage assay using 
purified recombinant wild-type human topo IIα and IIβ (Bandele and Osheroff 2007) 
where it was shown that these compounds were active against topo IIβ. Genistein (50 
µM) was shown to be the most effective of the bioflavonoids tested and stimulated 
enzyme-mediated DNA cleavage ~10-fold.  
Benzene and Its Metabolites 
Benzene is a ubiquitous pollutant and is one of the top production chemicals in 
the United States. It is used in the manufacturing industry and is a combustion product of 
cigarette smoke. Benzene is carcinogenic and causes primarily hematopoietic cancers in 
humans. It has been reported that it causes DNA damage through its metabolites, 
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especially 1,4-benzoquinone (Lindsey, Bromberg et al. 2004). This study reported that 
1,4 benzoquinone is a strong topo II poison in vitro using purified human topo IIα in a 
plasmid DNA cleavage assay. It stimulates DNA cleavage by topo II ~ 8-fold at a 
concentration of 25 µM, and at sites close to defined chromosome breakpoints in 
leukemia. Benzene and its metabolites including benzoquinone also increase the 
homologous recombination in a Chinese hamster ovary (CHO) cell line due to generation 
of oxidative stress (Winn 2003). A CHO cell line containing a neo direct repeat 
recombination substrate underwent increased recombination (2.7-, 5.5-, or 6.9-fold) with 
exposure to 1, 10, or 30 µM benzoquinone respectively. Benzene metabolites 1,4 -BQ (1-
10 µM) or 1,4-HQ ( 10-100 µM) cause DNA damage and fragmentation, as detected by 
pulsed-field gel electrophoresis in cultured HL60 cells though the generation of H2O2 
leading to apoptosis (Hiraku and Kawanishi 1996).  
Other drugs and pesticides  
Use of certain other drugs and pesticides has also been reported to be associated 
with MLL gene fusions. A pilot case-control study (Alexander, Patheal et al. 2001) that 
investigated the risk of infant acute leukemia due to transplacental chemical exposure 
reported that several groups of drugs including herbal medicines, the nonsteroidal anti-
inflammatory drug, dipyrone and exposure to pesticides like mosquitocidals including 
Baygon were associated with causing MLL gene fusions. This study was done across 
different countries and ethnic groups. 136 population-based cases and 266 controls were 
included in most centers. MLL rearrangement status was derived by Southern blot 
analysis, and maternal exposure data were obtained by interviews using a structured 
questionnaire. 
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Maternal use of dipyrone during pregnancy was shown to be associated with 
infant acute leukemia (IAL) in a hospital-based case-control study conducted in different 
cities of Brazil (Pombo-de-Oliveira, Koifman et al. 2006). A total of 202 children with 
newly diagnosed IAL (infant acute leukemia) were enrolled along with 440 age-matched 
controls. The magnitude of the odds ratio of 1.45 for maternal exposure to dipyrone 
suggested the occurrence of interactions between dipyrone exposure during pregnancy 
and MLL rearrangements, leading to IAL development. 
I am interested in investigating the potential of the compounds mentioned in this 
section to induce MLL translocations. 
1.10 Structures of topo II inhibitors used in this study 
 Etoposide is composed of a polycyclic ring system (rings A-D), a glycosidic 
moiety at the C4 position, and a pendant ring (E ring) at the C1 position (Figure 6) 
(Baldwin and Osheroff 2005, Wilstermann, Bender et al. 2007, Bender, Jablonksy et al. 
2008). The binding of etoposide to topo II is driven by interactions with the A-ring and 
the B-ring (Bender, Jablonksy et al. 2008). The E-ring is important for etoposide function 
(Wilstermann, Bender et al. 2007). Alterations in the E ring dramatically impair 
etoposide ability to enhance DNA cleavage mediated by topo II since every substituent 
on the E ring is intimately associated with the topo II protein in the binary complex 
(Wilstermann, Bender et al. 2007, Bender, Jablonksy et al. 2008). The glycosidic moiety 
of etoposide does not contact the enzyme and it is not clear if the moiety plays any role in 
enhancing topo II mediated DNA cleavage (Wilstermann, Bender et al. 2007, Bender, 
Jablonksy et al. 2008). 
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Figure 6: Etoposide structure showing the rings A, B, C, D and E, and the glycosidic 
moiety at position C4. 
 
 
 Multiple bioflavonoid compounds such as genistein and quercetin have also been 
shown to inhibit topo II  and topo II  activity (Bandele and Osheroff 2007). Both these 
compounds have been shown to induce in vitro cleavage in the MLL gene and contribute 
to infant leukemia (Strick, Strissel et al. 2000). Bioflavonoids are divided into three main 
groups: flavones, flavonols, and isoflavones. The 5-OH in genistein plays an important 
role in mediating genistein binding to topo II and the 4`-OH plays a significant role in 
genistein function (Figure 7) (Bandele and Osheroff 2007). Etoposide, genistein and 
quercetin contain pendant rings that feature a 4`-OH group that is essential for drug 
action (Figures 6 and 7) (Long, Musial et al. 1984, Elsea, McGuirk et al. 1993, Bandele 
and Osheroff 2007).  
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Figure 7: Quercetin (flavonol) (a), genistein (isoflavone) (b), luteolin (flavone) (c), and 
myricetin (flavonol) (d) structures. The 4`-OH group in the pendant ring is important in 
genistein function and the 5-OH mediates binding to topo II (Bandele and Osheroff 
2007).  
 
 
 In addition to etoposide and bioflavonoids, two other compounds – dipyrone and 
benzoquinone were included in the study for their distinct mechanisms of action. 
 Dipyrone is a nonsteroidal anti-inflammatory drug and its use has been shown to 
be associated with MLL gene fusions as described above. 
(c) (d) 
(a) (b) 
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Figure 8: The structure of dipyrone 
 
 
 Benzoquinone has been shown to be a strong topo II inhibitor in in vitro studies as 
described above. It is a non-bioflavonoid thought to have a distinct mechanism of action, 
and is clinically associated with non-MLL-rearranged leukemias. 
 
Figure 9: The structure of benzoquinone 
 
 
1.11 DNA repair of DSBs  
A possible mechanism by which these topo II inhibitors cause MLL-AF9 
translocations is by inducing DSBs in the DNA. DSBs are highly recombinogenic, 
increasing the exchange of information between two DNA duplexes by several orders of 
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magnitude; thus mammalian cells are at risk for rearrangements arising during DSB 
repair (van Gent, Hoeijmakers et al. 2001, Elliott and Jasin 2002) 
 The major DNA repair pathways include homologous recombination (HR) and 
non-homologous end joining (NHEJ). HR involves using a homologous sequence, 
usually on the undamaged sister chromatid or homologous chromosome as a template to 
repair the DNA damage (San Filippo, Sung et al. 2008). It has the highest potential for 
accurate repair (Essers, van Steeg et al. 2000). One of the models of HR repair is called 
double-strand break repair (DSBR) (Szostak, Orr-Weaver et al. 1983).This pathway 
involves (a) DSB creation, (b) processing of the broken ends to result in 3’ single strand 
ends, (c) recombinase filament formation on the ssDNA ends, (d) strand invasion into a 
homologous sequence to form a D-loop intermediate, (e) DNA polymerase extension of 
the invading strand, (f) annealing of the extended strand to capture the second DSB end, 
(g) formation of two Holliday junctions (HJ) and (h) resolution of the HJs resulting in 
crossover or non-crossover products (San Filippo, Sung et al. 2008). Synthesis-dependent 
strand annealing (SDSA) is another model of HR in which after DNA strand invasion and 
repair DNA synthesis, the invading strand is displaced and anneals with the second DSB 
end (Strathern, Klar et al. 1982, Nassif, Penney et al. 1994, Ferguson and Holloman 
1996, San Filippo, Sung et al. 2008). In the single strand annealing (SSA) method, the 
DSB ends are resected and the single strand resected ends basepair and anneal to each 
other independent (Symington 2002)  of strand invasion into a homologous sequence 
(Lin, Sperle et al. 1984, Fishman-Lobell, Rudin et al. 1992, Symington 2002).  
 The HR processes are mediated by several factors. The MRN complex comprising 
of Mre11, Rad50 and Nbs1 is involved in DNA binding and DSB end resection (Sung 
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and Klein 2006). Replication Protein A (RPA) binds to the newly resected ssDNA with 
high affinity and removes secondary structures (Sugiyama, Zaitseva et al. 1997). The Rad 
51 protein forms a complex with Rad 52, and displaces RPA from the ssDNA, forming a 
presynaptic filament (Milne and Weaver 1993). BRCA2 binds DNA, physically interacts 
with Rad51 and is needed for the formation of DNA damage induced Rad51 foci (Yuan, 
Lee et al. 1999, Yang, Li et al. 2005, San Filippo, Chi et al. 2006). Rad54 and Rad54B 
associate with Rad51, has dsDNA-dependent translocase activity, stimulates the D-loop 
reaction to initiate DNA repair synthesis and has the ability to remove Rad51 from 
dsDNA (Tanaka, Kagawa et al. 2002, Tan, Kanaar et al. 2003, Heyer, Li et al. 2006, 
Wesoly, Agarwal et al. 2006, Zhang, Fan et al. 2007, San Filippo, Sung et al. 2008). 
 NHEJ, on the other hand, requires minimal or no sequence homology to repair 
damage, and is usually not error free (Essers, van Steeg et al. 2000). Nucleases such as 
FEN-1 exonuclease are involved in end-processing of the DSB break, before ligation of 
the broken ends, resulting in loss of nucleotides (Pastwa and Blasiak 2003). DNA 
polymerases µ and λ, involved in NHEJ, can slip back on their template strand during 
synthesis, resulting in direct repeats (Dominguez, Ruiz et al. 2000, Jager, Bocskor et al. 
2000, Welzel, Le et al. 2001, Bebenek, Garcia-Diaz et al. 2003). Template independent 
addition of nucleotides by pol µ sometimes folds back on itself to form a stem-loop 
structure that can act as a primer/template substrate (Ramadan, Shevelev et al. 2004, Gu, 
Lu et al. 2007, Lieber 2010). This will result in inverted repeats at the NHEJ junctions, 
and has been observed in chromosomal translocations in humans (Jager, Bocskor et al. 
2000, Welzel, Le et al. 2001). NHEJ mode of DNA repair is presumed to occur in the 
formation of translocations observed in AML (Acute Myeloid Leukemia) and ALL 
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(Acute Lymphoid Leukemia) patients, because of the absence of significant homology at 
mapped breakpoint junctions (Weinstock, Elliott et al. 2006). 
 NHEJ is initiated by the binding of the Ku 70/80 heterodimer to the ends of the 
DSB (Mimori and Hardin 1986, Blier, Griffith et al. 1993, Weterings and Chen 2008). 
The Ku-DNA complex recruits the DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs) in order to form a synaptic complex bridging the DSB ends (Ma, Lu et al. 
2004, Weterings and Chen 2008). Artemis, forming a complex with DNA-PKcs, can 
endonucleolytically cut DNA overhangs (Ma, Pannicke et al. 2002). DNA polymerases µ 
and λ can add in nucleotides; polymerase µ can perform template independent synthesis 
(Sonoda, Hochegger et al. 2006). The Ligase IV/XRCC4/XLF complex catalyses the 
ligation reaction of the processed DNA ends (Gu, Lu et al. 2007, Gu, Lu et al. 2007, 
Weterings and Chen 2008).  
1.12 The connection between DSBs and epigenetic alterations 
The bioflavonoid compounds that induce DSBs due to topo II inhibition are also 
implicated in epigenetic changes. Epigenetic changes such as chromatin remodeling and 
histone-specific modifications control DSB detection, signaling and repair. The factors 
that influence this complex process have been reviewed (Pandita and Richardson 2009). 
After damage to the DNA, chromatin structure is altered by ATP-dependent chromatin 
remodeling, incorporation of histone variants into nucleosomes, and covalent histone 
modifications. These histone modifications include phosphorylation of histone H1; 
acetylation of H2A, phosphorylation and ubiquitination of H2AX; acetylation and 
methylation of H3; and phosphorylation and acetylation of H4. Among the different 
histone modifications, phosphorylation of all four histones as well as the variant H2AX 
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plays a primary role in DNA damage response by facilitating access of repair proteins to 
DNA breaks. 
It has been demonstrated that heterochromatic DSBs are generally repaired more 
slowly than euchromatic DSBs (Goodarzi, Noon et al. 2008). Studies have shown that 
HAT (histone acetyl transferase) complexes act with the ATP-dependent SWI/SNF and 
RSC-containing chromatin remodeling complexes to facilitate DNA repair (Kimura and 
Horikoshi 1998).  
Heterochromatin (HC) is the more tightly compacted DNA structure acts as a 
barrier for some DNA repair processes. The role of ataxia telangiectasia (ATM) and its 
damage response mediator proteins in overcoming the constraints posed by 
heterochromatin superstructure in DNA repair has been reviewed (Goodarzi, Jeggo et al. 
2010). Following DSB induction, the heterochromatin undergoes a series of events to 
implement the dynamic and localized changes that are necessary for DSB repair. DSB 
repair may be stalled within HC regions if these changes fail to take place. KAP-1 co-
repressor and HP1 chromodomain protein are two HC factors that are targets of the DNA 
damage response. Activation of the ATM signaling pathway and the subsequent 
phosphorylation of KAP-1 trigger the HC modifications required for DSB-repair.  
Some of the key epigenetic regulatory processes involved in DSB repair have 
been reviewed (Orlowski, Mah et al. 2011). This review also discusses the potentially 
pathological repercussions of incomplete or incorrect restoration of chromatin structure 
resulting in a DSB-induced epigenetic memory of damage. Phosphorylation of histone 
variant H2AX generates γH2AX which spreads over large chromatin domains 
surrounding the DSB. This leads to large-scale chromatin reorganization within the DSB 
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vicinity to recruit repair factors, recombination proteins and chromatin remodeling 
complexes involved in NHEJ and HR repair pathways. Phosphorylation of histones H2B 
and H4 also occur in DSB repair response. Histone acetylation, methylation and 
ubiquitination are the other histone modifications that take place, also mentioned above. 
DNA methylation, which is a significant epigenetic mark of transcriptional inactivity, 
also plays a role in DSB damage response. A DSB, in the course of repair, can 
occasionally leave a remnant in the form of an epigenetic mark. If such incorrect 
epigenetic modifications are mitotically stable, and if they relate to tumor suppressor 
silencing or the ectopic expression of an oncogene, they could play a role in 
carcinogenesis. 
Polycomb group proteins, which have well-established roles in gene regulation, 
were recently found to accumulate on chromatin surrounding DNA damage (Gieni, 
Ismail et al. 2011). Polycomb group proteins (PcG) are a family of proteins that form 
complexes involved in the epigenetic regulation of gene expression. Polycomb repressive 
complexes (PRC) catalyze post-translational modifications critical to their gene silencing 
function, including histone H3K27 trimethylation and histone H2A ubiquitination. This 
complex may also be involved in DNA methylation. PcG and PRC components found to 
respond to DNA damage include BMI-1, MEL-18, EZH2 methyltransferase, EZH1, 
EED, SUZ12. Gene silencing activity of PcG proteins, like mono-ubiquitylation of H2A 
is exploited during DSB repair. 
Chromatin dynamics at DSBs exert a powerful influence on the process of DSB 
repair (Xu and Price 2011). Heterochromatin and euchromatin utilize distinct remodeling 
complexes and pathways for DSB repair. Changes in chromatin architecture that occur 
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for repair of DSBs include nucleosome eviction from DSBs, relaxation of 
heterochromatin structure, and localized chromatin destabilization at DSBs.  
The recent advances in the understanding of the interplay between chromatin 
remodeling and DNA damage response have been reviewed (Lai, Li et al. 2013). Signal 
transduction pathways in DNA damage response (DDR) communicate with chromatin-
remodeling factors. The p53 signaling pathway responds to DNA damage by regulating 
DNA repair. In addition to DNA repair, the p53 signaling pathway is also associated with 
chromatin structure changes that mainly involve the histone acetyl transferase Tip60 
following DNA damage. Numerous chromatin-remodeling factors that are involved in 
DNA methylation and demethylation also play a role in DDR. In the thymus, genotoxic 
stress exposure decreases DNA methylation globally by a reduction in the levels of 
enzymes involved in DNA methylation such as DNA methyltransferase 1 (DNMT1), 
DNMT3a, DNMT3b and methyl-binding proteins MeCP2 and MBD2. Several 
chromatin-remodeling factors form a complex with DDR-related proteins in response to 
DNA damage. Scaffold matrix attachment region 1 (SMAR1) binds other SMAR1 
elements along with HDAC1 and p53, forming a repressor complex to downregulate 
transcription. The chromatin-remodeling factor Tip49 recruits Rad51 to DNA damage 
sites. 
1.13 Long-term impact of chromatin remodeling and DNA damage in stem cells induced 
by environmental, dietary and therapeutic agents 
 In addition to the topo II inhibitors mentioned above, there are several other 
agents that have the potential of causing genetic and epigenetic alterations in 
stem/progenitor cells. These have been discussed in appendix II (Bhawana Bariar and 
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Christine Richardson, “Long-term impact of chromatin remodeling and DNA damage in 
stem cells induced by environmental, therapeutic and dietary agents” manuscript in 
review). 
Commonly occurring environmental agents, and commonly used dietary and 
therapeutic agents can induce several different changes at the cellular and molecular 
levels. Some of the examples of environmental agents that have been shown to alter 
epigenetic modifications are metals, UV radiation, bisphenol A, alcohol, aldehydes, and 
cigarette smoke. Among dietary agents, many plant-derived compounds e.g. 
bioflavonoids are being used as dietary supplements which have the potential of causing 
epigenetic changes in the chromatin. Therapeutic agents such as drugs used in the 
treatment of cancer, estrogens used in hormone supplement therapy can induce such 
changes as well. Exposure to these agents can induce epigenetic alterations by histone 
modification, changes in cell differentiation, modulation of cellular signal transduction 
pathways including DNA damage repair pathways, changes in gene expression, 
illegitimate DNA repair leading to genome rearrangements and carcinogenesis. Multiple 
lines of evidence through studies in in vitro and in vivo models have shown that in utero 
exposure to environmental toxicants can cause epigenetic modifications which in turn 
induce alterations in gene expression that may persist throughout life as reviewed (Singh 
and Li 2012). These modifications include DNA methylation, histone modification, and 
expression of non-coding RNAs (including microRNAs) and play a role in the etiology of 
complex diseases such as cancer and diabetes. 
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1.14 My thesis work 
 Infant acute leukemias account for ~30% of all malignancy seen in childhood 
across the Western world. They are aggressive and characterized by rapid onset shortly 
after birth. The majority of these (~80% ALL and ~60% AML) have rearrangements 
involving the MLL gene. Although MLL fusion to more than 75 genes have been 
identified, AF9 is one of its most common translocation partners. MLL breakpoint 
sequences associated with infant acute leukemia are similar to those in secondary AML 
following exposure to the topo II poison etoposide. This similarity led to the hypothesis 
that exposure during pregnancy to biochemically similar compounds may promote infant 
acute leukemia. Some studies have shown an epidemiological link between bioflavonoid 
intake and increased incidence of MLL-rearranged infant leukemias. These bioflavonoids 
have also been shown to inhibit topoII in in vitro DNA cleavage assays. Hundreds of 
unregulated nutritional supplements are widely available and perceived to prevent 
cardiovascular disease, inflammation and cancer. However, their potential to promote 
leukemic translocations should be determined.  
 The influence of hematopoietic-specific developmental programs on the repair of 
DNA damage such as DSBs and the initial molecular events that lead to translocations, 
which are a hallmark of leukemia, lymphoma and soft-tissue sarcomas is not well 
understood. The mechanisms by which specific translocations associated with leukemias 
occur remain controversial. Specific gene loci may be particularly susceptible to breakage 
or aberrant repair only when expressed or as open chromatin within certain hematopoietic 
subpopulations. Alternatively, these translocations may arise with equal frequency in all 
cell types, but specific malignant outcome results due to preferential selection or survival. 
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Clinical parameters and tumor pathology of multiple tumor types has suggested that stem 
cells are the target of the initiating lesion. Stem cells could act as tumor initiators because 
they possess a greater capacity for proliferation into multiple lineages even if the initial 
event is no more likely in any particular cell, or because they are more susceptible than 
more differentiated cell types to the initial acquisition of genome alterations. The survival 
and stability of the cells that acquire these alterations is another important factor. It is also 
not known whether the genome rearrangements characteristic of leukemia and lymphoma 
arise as part of normal DSB repair processes or if they require signaling pathways 
specific to the DNA damaging agents discussed above. 
 A model system to directly examine the relative role of specific repair pathways 
to prevent or promote specific genome rearrangements has been lacking. There is 
preliminary association between bioflavonoids in the generation of specific infant 
leukemias, and multiple bioflavonoid compounds have been shown to inhibit topo II 
activity and promote DNA cleavage. However no genetic assay yet has been able to 
definitively determine the relative potential for each of these compounds to promote 
AML associated translocations. My goal was to test the hypotheses that 1) MLL and AF9 
bcrs undergo DSBs, and are highly recombinogenic independent of chromosomal 
context, and in the absence of a leukemic fusion protein; and 2) a number of topo II 
inhibitors have the potential to promote these translocations analogous to those observed 
in infant leukemia. I demonstrate here the sensitivity of the MLL and AF9 bcrs to topo II 
poisons and bioflavonoids independent of their normal chromatin context and 
independent of the formation of a leukemic fusion protein. This genetic assay does not 
30 
 
rely on IPCR that requires elimination of artifacts or less physiologically relevant internal 
deletions or intronic alterations from analysis.  
 Chapter 3 describes the establishment of a reporter gene model system to screen 
for the frequency of MLL-AF9 translocation events. I developed reporter mouse 
embryonic stem cell lines that contain two transgene constructs- (1) the MLL bcr 
fragment containing a genetically-engineered GFP 5’ exon, and (2) the AF9 bcr 
containing a genetically-engineered GFP3’ exon. A translocation between the two bcrs 
reconstitutes the full-length GFP transcript resulting in quantifiable green fluorescence. 
The technical details are presented in chapter 2 which describes the materials and 
methods. 
 Chapter 4 describes the quantification of GFP+ colonies after endonuclease I-SceI 
expression which induces directed DNA breaks in reporter cell lines. The optimum 
conditions for the model system and isolation of green fluorescent colonies by 
microscopy was established by inducing directed DSBs in the reporter transgene 
constructs at the specific I-SceI restriction sites that have been engineered in to the 
constructs. I-SceI expression in these cell lines created DSBs at these sites, leading to a 
translocation between the MLL-5’GFP  and AF9-3’GFP reporter constructs leading to the 
expression of GFP protein and green fluorescence in cells that undergo this genomic 
rearrangement. The results describe the comparison of frequencies of appearance of 
GFP+ cells among three different and independently obtained reporter cell lines and the 
possible factors that could lead to different frequencies. Finally, the chapter includes the 
DNA sequence analysis of the repair junction of a GFP+ clone that was isolated and 
expanded after I-SceI expression. The sequence analysis indicates the use of non-
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homologous end joining (NHEJ) repair pathway to repair the DSB created by I-SceI, thus 
resulting in MLL-AF9 translocation. 
 Chapter 5 describes the quantification of GFP+ colonies after treating the reporter 
cell lines with varying doses of different topo II inhibitors including the 
chemotherapeutic drug etoposide and different bioflavonoid compounds which are found 
in our diet and are also used as nutritional supplements. The results include comparison 
of frequencies of appearance of GFP+ colonies among three different and independently 
obtained reporter cell lines and among the different compounds used and the possible 
explanations for these differences. Cells were treated with etoposide, quercetin, genistein, 
luteolin, myricetin, dipyrone, or benzoquinone for 1 hour at 25 µM - 200µM 
concentrations then allowed to repair and proliferate in culture. GFP+ fluorescent 
colonies as a result of MLL-AF9 translocations were readily scorable by 96 hours in a 
dose-dependent manner.  
 As previously demonstrated, totipotent stem cell viability was extremely impaired 
by multiple concentrations of etoposide, but the surviving fraction exhibited a significant 
number of MLL-AF9 translocations (frequency of 1.7 X 10-4). Bioflavonoids genistein 
and quercetin (75 µM) were also potent promoters of MLL-AF9 translocations in 
totipotent stem cells at roughly similar frequencies as etoposide. The significance of this 
model system is apparent from treatment of stem cells with benzoquinone that was not 
sufficient to produce MLL-AF9 translocations following exposure to concentrations up to 
125 µM (frequency < 0.1 X 10
-6
). Benzoquinone is a non-bioflavonoid thought to have a 
distinct mechanism of action and clinically associated with non-MLL-rearranged 
leukemias. This system is a direct measure of the sensitivity of the MLL and AF9 bcrs to 
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topo II poisons and bioflavonoids independent of their normal chromatin context and 
independent of formation of a leukemic fusion protein. In addition, the system allows for 
rapid and reproducible screening of hundreds of compounds that may have the potential 
to promote leukemogenic translocations in early stem cell and more differentiated cell 
subpopulations analogous to the events observed in infant acute leukemias. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
 
 The tables and figures referred to in this chapter have been included in the results 
chapters 3, 4 and 5. Please refer to those chapters for the tables and figures as 
appropriate. 
2.1 Creation of transgene constructs 
The green fluorescent protein (GFP) gene was engineered to contain an 
adenovirus 227 bp intron. This construct was then separated into two DSB repair 
substrate constructs. One construct contains the 5’ half of the GFP gene (containing the 
promoter), a splice donor (SD), and an adenovirus intron sequence ligated to an I-SceI 
endonuclease recognition site. The second construct contains an I-SceI recognition site, 
and an adenovirus intron sequence, a splice acceptor (SA), and 3’ half of the GFP gene. 
These DSB-inducible recombination reporter constructs were then engineered into human 
MLL and AF9 bcrs. The first construct containing the 5’ half of the GFP gene was 
inserted into intron 11 of the human MLL bcr BamHI-BamHI fragment. The locus of 
insertion was chosen based on its association with a high proportion of therapy-related 
leukemia translocation breakpoints. (Broeker, Super et al. 1996). The second construct 
containing the 3’ half of the GFP gene was inserted into intron 8 of the human AF9 bcr2 
region (Strissel, Strick et al. 2000). The regions where the GFP reporters were inserted 
were upstream (5’GFP) or downstream (3’GFP) of known strong topoII cleavage sites 
and mapped breakpoints identified in clinical samples of infant AML and t-AML cases. 
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Transgene constructs were prepared through standard restriction digestions and ligations 
using enzymes from New England Biolabs Inc.  Restriction digests were performed on 
the backbone and insert sequences were ligated into the backbone. Cloning of these 
constructs was done using the TOPO TA cloning kit provided by Invitrogen according to 
the manufacturer’s instructions and transforming competent E. coli TOP10 cells provided 
by Life technologies according to the manufacturer’s instructions, growing the cells and 
harvesting plasmid DNA from them. The constructs were verified by agarose gel 
electrophoresis. Introduction of an I-SceI expression plasmid will lead to the formation of 
specific and unique DSBs at these engineered sites. 
2.2 Generation of transgenic cell lines 
The transgene constructs were electroporated into mouse embryonic stem (ES) 
cells (Richardson, Moynahan et al. 1998, Elliott, Richardson et al. 2005). The two 
constructs were randomly integrated into the genome of mouse ES cells through two 
separate rounds of electroporation.  The electroporation protocol is as follows.  
Mouse EtG2a ES cells growing in standard ES medium were washed with 1X 
PBS (phosphate buffered saline), treated with 0.25% trypsin for 10 minutes at 37
o
C and 
centrifuged at 1000 rpm for 10 minutes. The cells were resuspended in 1X PBS and 
counted using a hemacytometer. Puromycin and neomycin resistance gene-containing 
plasmids were used as positive selection markers and were cotransfected with the 
transgene constructs. Random integration resulted in puro or neo expression selectable 
with the drugs puromycin or neomycin.  
The neomycin plasmid was electroporated along with the MLL transgene into a 
single cell suspension of 20 million mouse ES cells. 24 hours post electroporation, the 
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media was changed to include G418. Upon growing in selection medium, surviving cells 
formed colonies (Richardson, Moynahan et al. 1998, Elliott, Richardson et al. 2005). The 
surviving colonies were identified, picked, grown and screened for the presence of a 
single copy of the MLL transgene by performing appropriate digests (BgIII/XbaI; 
BamHI/BglII; EcoRV) (New England Biolabs Inc.) followed by standard Southern Blots. 
The full length GFP gene was used as the probe. Single copy MLL clones were selected, 
grown and expanded (Table 1). One of the clones, MLL-F2, was selected and 
electroporated with the AF9 transgene along with puromycin (Table 1). 20 million cells 
were used for the electroporation. 24 hours post electroporation, selection medium 
containing puromycin was used. Surviving colonies were picked, grown and screened for 
the presence of a single copy of the AF9 transgene.  
The isolated surviving clones were expanded in 96 well plates and screened by 
both PCR (using 5’ primers GFP-bcl and GFP 5’ intron 2; and 3’ primers GFP-nco top 
and GFP-orf 3’) and Southern blotting using appropriate digests (KpnI; BamHI; NcoI; 
BamHI/BglII; XhoI; PstI) (New England Biolabs Inc.) and the full length GFP gene as a 
probe to identify single copy clones. Selected clones were expanded and used for further 
experiments (Tables 1 and 2). 
2.3 DSB induction in transgenic cell lines by I-SceI expression 
To create translocation events between the two transgene constructs, DSBs were 
induced by ISceI expression through electroporation of the pCBASce vector which 
contains the ISceI gene in it (Richardson, Moynahan et al. 1998). Cell lines MAG 32, 
MAG 32A and MAG 68 were used for the electroporations (Table 3). All these reporter 
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cell lines have a single copy of the MLL and AF9 transgene randomly integrated into the 
genome (Tables 1 and 2) (Figure 10).  
In each experiment, three sets of electroporations were performed on 20 million 
cells per set. Out of the three cohorts, one had no DNA (negative control), one cohort had 
40 µg of the GFP gene (NZE-GFP, P. Sung GFP #2) (positive control), and the third 
cohort with 20 µg of the I-SceI plasmid pCBASce. The electroporated cells were plated 
on 5 plates per cohort resulting in 4 million cells per plate. One plate per cohort was used 
to count the number of surviving cells 24 hours post electroporation, using a 
hemacytometer (Richardson, Moynahan et al. 1998, Elliott, Richardson et al. 2005). All 
plates from the three cohorts were examined each day for GFP expression using the 
fluorescent filter on an inverted microscope. Green fluorescent colonies seen were 
captured by Zeiss camera, isolated using a micropipette, expanded and examined each 
day for GFP expression. Genomic DNA from the colonies was isolated and used for PCR 
using primers GFP-bcl and GFP-orf 3’ to check for the occurrence of a translocation 
between the MLL and AF9 transgenes and thus amplification across the repair junction. 
Some of the PCR products were cloned in TOPO TA vector and sent for sequencing to 
Sequetech Corporation, California and the sequence was analyzed across the repair 
junction. 
2.4 DSB induction in MAG cell lines by treatment with topo II inhibitors 
10
7
 cells (counted using Orflo Moxi Z automated cell counter) from the MAG cell 
lines were treated with different doses of the various topo II inhibitor compounds in 15 
ml of ES cell medium on 100 cm
2
 plates for one hour at 37
o
C. The cells on each plate 
were washed with 1X PBS, trypsinized and replated on to three plates after centrifugation 
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at 1000 rpm for 10 minutes and resuspension in fresh ES cell medium. The plates from 
all the doses were washed with 1X PBS (twice daily on the first two days after treatment, 
and once every day after that), supplemented with fresh ES medium and observed every 
day using the fluorescent filter on the inverted microscope for any GFP expression and 
thus green fluorescence. Any green fluorescent colonies observed were captured by Zeiss 
camera fitted to the microscope, isolated using a micropipette, expanded and examined 
each day for GFP expression. Genomic DNA from the colonies was isolated and used for 
PCR using primers GFP-bcl and GFP- orf 3’ to check for the occurrence of a 
translocation between the MLL and AF9 transgenes and thus amplification across the 
repair junction. Some of the PCR products were cloned in TOPO TA vector and sent for 
sequencing to Sequetech Corporation, California and the sequence was analyzed across 
the repair junction. 
2.5 Cell viability assays 
1 X 10
6
 EtG2a mouse ES cells each were plated onto 3 plates each per dose 0, 25, 
50, 75, 100 and 200 µM) of a test compound. After treatment for one hour at 37
o
C, the 
number of surviving cells were counted for each dose at 24, 36 and 72 hours using the 
automated Moxi cell counter. The cells were trypsinized for 10 min at 37
o
C, resuspended, 
diluted and counted in a 75 µl volume. The percentage of surviving cells was plotted on a 
graph. 
2.6 FACS (Fluorescence Activated Cell Sorting) 
FACS was performed on the cells treated with different doses of etoposide. The 
FACSAria (BD Biosciences) machine was used to sort GFP+ cells. Selected plates were 
washed with PBS, trypsinized, centrifuged at 1000 rpm for 10 minutes and resuspended 
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in fresh ES cell medium. The cell suspension was filtered using sterile filter tubes before 
performing FACS on them. Sorted green fluorescent cells were plated onto 96 well plates 
at the rate of 5 events per well and allowed to expand. The survival of cells after FACS 
treatment was tabulated. 
2.7 DNA extraction and analysis 
ES cells on a plate were washed with PBS and trypsinized for 10 min. After 
trypsin treatment, the cells were resuspended by adding fresh medium and transferred to a 
conical tube. They were centrifuged at 1000 rpm for 10 min and the supernatant aspirated 
off. The cell pellet was treated with 0.5mg/ml of Proteinase K resuspended in DNA-PK 
buffer. The samples were placed at 60
o
C overnight. The next day the volume was 
transferred to eppendorf tubes, an equal amount of phenol added, mixed by inverting and 
centrifuged at 13,000 rpm for 10 minutes. The top aqueous layer was then transferred to a 
new tube and the phenol wash repeated followed by a wash with phenol-chloroform 
mixture. DNA from the final aqueous layer was precipitated using 3% sodium acetate and 
70% ethanol and the pellet was dissolved in TE buffer containing RNase. The tubes were 
placed at 37
o
C for one hour and the concentration of DNA measured using a nanodrop. 
The extracted DNA was then used for PCR analysis and Southern blots as explained 
above. 
 
 
 
 
 
 
 
 
CHAPTER 3: CREATION OF DOUBLE TRANSGENIC MLL-AF9  
GFP REPORTER CELL LINES 
 
 
3.1 Generation of single copy double transgenic clones screened by Southern Blotting 
and PCR 
The human MLL bcr-5’GFP-intron-I-SceI construct was electroporated into 
EtG2a mouse ES cells along with the neomycin reporter gene. The cells were allowed to 
grow in selection medium containing neomycin. A total of 123 surviving clones were 
identified (Table 1). A panel of restriction digests followed by Southern Blots was 
performed. Four clones were identified as having a single copy of the MLL transgene 
each. The clones were named MLL-13, MLL-G2, MLL-F2 and MLL-E8 (Table 1).  
The MLL-F2 clone was selected, expanded and electroporations were performed 
using the human AF9 bcr2-3’GFP-intron-ISceI construct along with puromycin as the 
selection marker. The cells were allowed to grow in selection medium containing 
puromycin. A total of 80 clones survived. A panel of restriction digests followed by 
Southern Blots was performed. Three clones were identified as having a single copy 
insert of the AF9 transgene. The clones were named MAG 32, MAG 60 and MAG 68 
(Table 1). Similar electroporations were also done on clone MLL-13 (Table 1). 
MAG 32 did not show MLL on Southern reproducibly, so we electroporated MLL 
back into it using hygromycin as the selection marker to generate clone MAG32A (Table 
1). Southern blotting was used to confirm the presence of both the transgenes (Figure 10).
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Electroporations were again performed with either the human MLL bcr-5’GFP-
intron-ISceI construct or the AF9 bcr2-3’GFP-intron-ISceI construct on a few parental 
clones using the appropriate drug resistant markers for cotransfection (Table 1).  This was 
done since these clones failed to show one of the transgenes in Southern blotting. The 
potential double transgenic clones were grown in selection medium, isolated and 
expanded for PCR analysis. 
These clones were screened using PCR (using 5’ primers GFP-bcl and GFP 5’ 
intron 2; and 3’ primers GFP-nco top and GFP-orf 3’) for the presence of a single copy 
each of both the transgenes. The clones selected from the PCR screen were analyzed by 
Southern blotting after the appropriate restriction digests.  
 
 
Table 1: Single copy clones screened by Southern blotting (SB) that contain MLL and 
AF9 GFP reporter transgenes. MAG32 did not show MLL on Southern reproducibly, so 
MLL was electroporated back into it. 
 
Transgene electroporated Parental Cell 
Line 
Drug 
Selection 
# Screened 
by SB 
Single 
Copy 
Clones 
MLL-5'GFP-intron-ISceI EtG2a Neomycin 123 F2, G2, 
13, E8 
AF9-3'GFP-intron-ISceI MLL-F2 Puromycin 80 MAG- 32, 
60, 68 
AF9-3'GFP-intron-ISceI MLL-13 Puromycin 60 5, 6, 30 
MLL-5'GFP-intron-ISceI MAG 32 Hygromycin 48 MAG 32A 
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Table 2: Clones screened by PCR that contain MLL and AF9 GFP reporter transgenes. 
Transgene electroporated Parental Cell 
Line 
Drug 
Selection 
# Screened 
by SB 
Single Copy 
Clones 
MLL-5'GFP-intron-ISceI MAG60 Hygromycin 96 M7, M21, 
M25, M29, 
M31, M35 
MLL-5'GFP-intron-ISceI 5 Hygromycin 44 M7, M6, 
M35 
MLL-5'GFP-intron-ISceI 6 Hygromycin 12 None 
MLL-5'GFP-intron-ISceI 30 Hygromycin 10 M2, M6, 
M8, M9, 
M5, M7 
AF9-3'GFP-intron-ISceI E8 Puromycin 96 5 
 
 
Parental clones MAG60, 5, 6 and 30 were electroporated with both MLL and AF9 
using neomycin and puromycin markers but repeated Southern blots only showed the 
presence of AF9, so MLL was added back by electroporation using hygromycin as a 
selectable marker. 30M2 showed both transgenes in Southern. Clones 30M2 and 5M35 
failed to grow when thawed from the frozen 96-well plates stored at -80
o
C (Table 2). 
Southern blotting was performed on MAG clones obtained after electroporations 
and drug selection as described above. Clones MAG 32A and MAG 32B showed both 
MLL-GFP and AF9-GFP transgenes in addition to MAG 32 and MAG 68 (Figure 10). 
However, MAG 32B was not used for future experiments since it failed to give any green 
fluorescent colonies after ISceI treatment. 
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Figure 10: Southern blots of clones containing single copy inserts of the MLL-5’GFP 
reporter and the AF9-3’GFP reporter transgenes. 
 
 
PCR screening as described above also confirmed the presence of MLL and AF9 
transgenes in some other clones mentioned in table 2 above. 
 
Figure 11: PCR confirming the insertion of MLL-GFP and AF9-GFP transgenes. 
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 The resultant MLL-AF9 double transgenic reporter stem cell lines contain MLL-
5’GFP and AF9-3’GFP genetically engineered constructs as shown in figure below: 
 
Figure 12: Map showing position of GFP-intron repair reporter constructs inserted in the 
human MLL (top) and AF9 (below) bcr regions. 
 
  
 SD stands for splice donor, SA stands for splice acceptor. Exons are shown as 
grey rectangles and numbered. MAR/SAR sites are indicated as yellow-white ovals (one 
in MLL and two in AF9). Topo II cleavage sites are indicated by green *.  
3.2 Conclusion 
 In this chapter I have described the establishment of a reporter gene system to 
screen for the frequency of MLL-AF9 bcr translocation events. A translocation between 
the two bcrs reconstitutes the full-length GFP transcript resulting in quantifiable green 
fluorescence.  
 
 
 
 
 
 
CHAPTER 4: ISCE-I EXPRESSION GENERATES FLUORESCENT (GFP+) 
COLONIES IN MAG REPORTER CLONES FOLLOWING DSB INDUCTION 
 
 
4.1 DNA repair reconstitutes GFP expression in MAG reporter clones  
 The reporter clones containing single copy inserts of the MLL as well as the AF9 
transgene constructs integrated randomly into the genome, were used for further 
experimentation to create DSBs in the MLL and AF9 bcr constructs. NHEJ repair 
resulting in translocations brought the 5’ GFP exon and the 3’ GFP exon together to 
create a restored GFP gene. Expression of the restored gene will result in GFP+ cells 
(Figure 13). 
 
Figure 13: Map showing position of the GFP-intron reporter constructs inserted in the 
human MLL (top) and AF9 (center) bcr regions; and NHEJ repair product (bottom). SD
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stands for splice donor, SA stands for splice acceptor. Exons are indicated as grey 
rectangles and numbered. MAR/SAR sites are indicated as yellow-white ovals (one in 
MLL and two in AF9). Topo II cleavage sites are indicated by green *. In MLL multiple 
repetitive elements in the same orientation are shown with different families of dispersed 
repeats indicated by different colors. These elements have not been mapped in the AF9 
locus.  
 
 
Each experiment included  
1. A negative control with no DNA 
2. A positive control with the GFP gene  
3. Endonuclease I-SceI expression plasmid, pCBASce.  
24 hours post electroporation, the number of surviving cells was calculated using a 
hemacytometer. The percentage of surviving cells was calculated.  
 NHEJ repair resulting in translocations can result in restoration of the GFP gene 
and green fluorescing cells (GFP+ cells). The electroporated cells were examined each 
day using the fluorescent filter on the microscope for the presence of GFP+ colonies 
(Figures 14 and 16). GFP+ colonies were identified on both the GFP+ control plates and 
the ISceI plates. These colonies were examined each day for continued GFP expression.  
4.2 GFP+ green fluorescent colonies are generated by I-SceI expression in reporter cell 
lines.  
 The electroporated cells were examined each day using the fluorescent filter on 
the microscope for the presence of GFP+ colonies (Figures 14 and 16). 
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Figure 14: Confocal microscopy images of GFP+ cells (left panel) and the phase contrast 
images (right panel), following electroporation of MAG 32 cells with ISceI.  
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Figure 15: GFP+ cells along with the phase contrast images of MAG 32 cells 
electroporated with GFP, the positive control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Confocal microscopy images of GFP+ cells (left panel) along with the phase 
contrast images (right panel) following electroporation of MAG 32A cells with ISceI. 
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4.3 The frequency of GFP+ colonies varies between three independently obtained MAG 
reporter cell lines, being the highest in MAG32A and the lowest in MAG68 
 The number of colonies identified was tabulated and the frequency of GFP+ 
colonies observed was calculated (Table 3). These data show that DSBs in the MLL and 
AF9 bcrs is sufficient to lead to aberrant NHEJ and translocations. 
 
 
Table 3. Induction of interchromsomal recombination and translocations by I-SceI-
induced DSBs between MLL and AF9 bcrs in three independent cell lines. 
 
Experiment/      % survival # of GFP+  
Cell Line  DNA  post-EP colonies    Frequency *  
 
MAG32A    expt. 1 no DNA 65%  0  < 7.6 X 10
-8
  
   GFP  41%  many  not calculated  
   I-SceI  38%  18     2.3 X 10
-6 
               expt.  2 no DNA 73%  0  < 6.8 X 10-8  
   GFP  46%  many  not calculated  
   I-SceI  40%  22     2.7 X 10
-6 
               expt.  3 no DNA 70%  0  < 7.1 X 10
-8
  
   GFP  46%  many  not calculated  
   I-SceI  42%  23     2.7 X 10
-6 
Avg. no DNA     < 7.2×10
-8
± 0.4×10
-8
 
Avg. I-SceI           2.5×10
-6
± 0.2×10
-6
^ 
 
 
 
Experiment/      % survival # of GFP+  
Cell Line  DNA  post-EP colonies    Frequency *  
 
MAG32 expt. 1 no DNA 57%  0  < 8.7×10
-8
  
   GFP  50%  many  not calculated  
   I-SceI  37%  11     1.4×10
-6
 
        expt.  2 no DNA 60%  0  < 8.3×10
-8
  
   GFP  50%  many  not calculated  
   I-SceI  38%  9     1.1×10
-6 
        expt.  3 no DNA 60%  0  < 8.3×10
-8 
 
   GFP  48%  many  not calculated  
   I-SceI  38%  10     1.3×10
-6
 
Avg. no DNA     < 8.4×10
-8
± 0.2×10
-8
 
Avg. I-SceI           1.2×10
-6
± 0.1×10
-6
$ 
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Table 3: (continued) 
 
Experiment/      % survival # of GFP+  
Cell Line  DNA  post-EP colonies    Frequency *  
 
MAG68 expt. 1 no DNA 78%  0  < 6.4×10
-8
  
   GFP  31%  many  not calculated  
   I-SceI  24%  1     0.2×10
-6
 
        expt.  2 no DNA 70%  0  < 7.1×10
-8
  
   GFP  35%  many  not calculated  
   I-SceI  29%  6     1.0×10
-6
 
        expt.  3 no DNA 75%  0  < 6.6×10
-8
  
   GFP  37%  many  not calculated  
   I-SceI  32%  5     0.7×10
-6
 
Avg. no DNA     < 6.7×10
-8
± 0.3×10
-8
 
Avg. I-SceI           0.6×10
-6
± 0.4×10
-6
# 
 
Three independently derived MAG cell lines were electroporated with the I-SceI 
endonuclease expression vector pCBASce. As a positive control, cells were 
electroporated with the GFP+ wild-type plasmid pCBAGFP. 2.0×10
7
 cells were 
electroporated in each sample. 
* The interchromsomal recombination and translocation frequency was calculated as the 
number of GFP+ clones per number of cells surviving electroporation (EP; as counted 24 
hrs postelectroporation).  
p values using an unpaired t-test: 
^ <0.0001 
$ 0.0019 
# 0.1532 
 
 
 
MAG32A: The two-tailed P value using an unpaired t-test is less than 0.0001. By 
conventional criteria, this difference is considered to be extremely statistically significant.  
MAG32: The two-tailed P value equals 0.0019. By conventional criteria, this difference 
is considered to be very statistically significant.  
MAG68: The two-tailed P value equals 0.1532. By conventional criteria, this difference 
is considered to be not statistically significant.  
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 The electroporated MAG clones were examined every day for the presence of 
GFP+ cells. Green fluorescent cells (usually visible at 96 hours) identified were isolated 
manually using the fluorescent filter on the microscope. The number of isolated green 
fluorescent colonies was tabulated and the frequency of isolated GFP+ colonies was 
calculated. 
 The average frequency was the highest in MAG 32A and the lowest in MAG 68. 
This could be explained by the insertion of the reporter transgenes at different sites in the 
genome, causing differences in the frequencies of DNA repair leading to translocations. 
4.4 Molecular analysis of a GFP+ clone suggests NHEJ at the DSB repair junction 
 A few green fluorescent clones were analyzed by PCR after expansion and 
isolation of genomic DNA. Clone 32A I-SceI G2 showed a band after amplification with 
GFP primers GFP 5’Intron 1F and GFP 3’Intron 2R. This PCR product was cloned in 
TOPO TA vector and sent for sequencing. The sequence at the breakpoint junction 
(Figure 17) shows that there was NHEJ without any nibbling in the introns but with the 
loss of ISceI sites. 
ANGANNCNNATAGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCC
AGTGTGATGGATATCTGCAGAATTCGCCCTTGGGACAGGATAAGTATGACAT
CATCAAGGAAACCCTGGACTACTGCGCCCTAGACGTGCAGCAAGCTTGACA
ACAAAAAGATTGTCTTTTCTGACCAGATGGACGCGGCCACCCTCAAAGGCAT
CACCGCGGGCCAGGTGAATATCAAATCCTCCTCGTTTTTGGAAACTGACAATC
TTAGCGCAGAAGTCATGCCCGCTTTTGAGAGGGAGTACTCACAAGGGCGAAT
TCCAGCACACTGGCGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTG
GCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAAT
TCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAA
TGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTC
GGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGA
GGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCG
CTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATA
CGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAA
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GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCC
ATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAANGTCAGA
GGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTNNAAG
CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCG
CTTTCTCCCTNCGGGAAGCGNGNGCTTNCTCATAGCTCACGCTGNAGNANCN
CANTTCGNN 
Figure 17: MAG32A-I-SceI-Green colony intron PCR sequence 
 
 
The sequences in blue and red denote the 5’ and 3’ halves of the GFP intron respectively. 
The nucleotide “A” in large black font denotes the 5’/3’ junction of the two introns. The 
I-SceI restriction site at the junction has been lost during repair. 
4.5 Conclusion 
 In this chapter I have described the quantification of GFP+ colonies after 
endonuclease ISceI expression which induces directed DNA breaks in reporter cell lines. 
The results describe the comparison of frequencies of appearance of GFP+ cells among 
three different and independently obtained reporter cell lines. 
 
 
 
CHAPTER 5: TOPO II INHIBITORS GENERATE GREEN (GFP+) COLONIES IN 
MAG REPORTER CLONES THROUGH DSB INDUCTION 
 
 
The next step after obtaining green fluorescent colonies by I-SceI expression in 
independently obtained reporter cell lines, was to test the potential of various topo II 
inhibitors to induce DSBs and lead to the formation of GFP+ colonies in these cell lines.  
5.1 Etoposide is the most toxic to cells, which also exhibit considerable sensitivity to 
bioflavonoids genistein and quercetin. 
Cell viability assays were performed on parental ETG2a cell lines to determine 
the sensitivity and cell survival percentages to various doses of these genotoxic 
compounds. 
 
Figure 18: Cell viability plots for genistein, benzoquinone and luteolin at 24, 48 and 72-
hour time points. 
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Figure 19: Cell viability plots for quercetin, myricetin, etoposide and dipyrone at 24, 48 
and 72-hour time points. 
 
 
 
Figure 20: Comparative analysis of cell viability and sensitivity to genotoxic compounds: 
genistein, quercetin, myricetin, luteolin, dipyrone, benzoquinone and etoposide at 24, 48 
and 72 hours. 
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A two-way ANOVA analysis (among compounds and doses) was performed 
comparing all the plots against etoposide using Bonferroni post-hoc analysis. The most 
significant differences as compared to the cell viability for etoposide are indicated in ***. 
These experiments demonstrate the sensitivity of mouse embryonic stem cells to 
these compounds that are topoII inhibitors. The chemotherapeutic drug etoposide is the 
most toxic to cells, and the cells also exhibit considerable sensitivity to bioflavonoids 
genistein and quercetin, whereas luteolin and benzoquinone seem to moderately affect the 
cells. 
These cell viability plots were used to determine the optimum dose to be used in 
the treatment experiments, broadly in the range of IC50 for each compound. The doses 
were also chosen based on previous studies which have described the physiological doses 
for these compounds. For example, three different doses of etoposide were used in the 
FACS analysis (Figure 25) (Libura, Ward et al. 2008). The dosage corresponds to the 
physiologically relevant dosage administered to patients during chemotherapy (Libura, 
Slater et al. 2005, Goodman, Gilman et al. 2008). 
5.2 GFP+ colonies are generated in MAG reporter cell lines upon treatment with topo II   
inhibitors 
MAG 32A cells were treated with different doses of myricetin, quercetin, 
genistein, luteolin, dipyrone, or benzoquinone for 1 hour at 75 µM - 200µM 
concentrations. They were then allowed to repair and proliferate in culture and observed 
every day for the appearance of green fluorescent colonies. MAG68 was treated with 
quercetin in the same way and allowed to repair and proliferate in culture. 
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Topo II inhibition results in DSB creation at various places in the genome, 
including the MLL and AF9 bcr construct regions. DNA repair of the DSBs created at the 
bcrs may result in translocations that brings the 5’ and 3’ halves of the GFP gene from 
the two constructs together. Expression of the reconstituted GFP gene resulted in GFP+ 
(green fluorescent) cells. GFP+ fluorescent colonies as a result of MLL-AF9 
translocations were readily scorable by 96 hours in a dose-dependent manner.  
Green fluorescent colonies were observed after approximately 96 hours of 
treatment and were followed, picked and expanded. GFP+ colonies are shown in figure 
21 below. 
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Figure 21: GFP+ ES colonies obtained after treatment of MAG 32A with topo II 
inhibitors 
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Figure 22: GFP+ ES colonies obtained after treatment of MAG 32A with genistein. The 
average frequency of GFP+ colonies after genistein treatment was calculated to be 1.2 X 
10
-6
. 
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5.3 Genistein and quercetin are the most potent promoters of MLL-AF9 translocations 
The frequencies of appearance of green fluorescent cells upon treatment of MAG 32A 
with various compounds in different doses are shown in table 4 below. 
 
 
Table 4. Induction of interchromosomal recombination and translocations by topo II 
inhibitors between MLL and AF9 bcrs in MAG32A cell line: a comparison of frequency 
of GFP+ cells generated by different compounds. 
 
Compound Expt Dose         # GFP+         Frequency*             Average frequency 
            Colonies                       at highest dose 
 
Genistein 1 75 µM  15        1.5 X 10-
6
    
  2 75 µM  8         8.0 X 10-
7
           
  3 75 µM  14         1.4 X 10-
6
 1.2 X 10-
6
± 0.3×10
-6
 
 
Quercetin 1 75 µM  8         8.0 X 10-
7 
      
 
  2 75 µM  14         1.4 X 10-
6
                     
  3 75 µM  11         1.1 X 10-
6 
1.1 X 10-
6
± 0.3×10
-6
     
 
Benzoquinone 1 75 µM  0         <1.0 X 10-
7
     
  2 125 µM 1         1.0 X 10-
7
        
  3 125 µM 1                   1.0 X 10-
7
       
  4 125 µM 0         <1.0 X 10-
7    
<0.06 X 10-
6
± 0.05×10
-6
 
  
Myricetin 1 75 µM  1         1.0 X 10-
7
 
  2 75 µM  1         1.0 X 10-
7  
 
  3 75 µM  2         2.0 X 10-
7
 0.1 X 10-
6
± 0.05×10
-6
 
  
Dipyrone 1 75 µM  0         <1.0 X 10-
7
 
  2 100 µM 0         <1.0 X 10-
7
 
  3 100 µM 1          1.0 X 10-
7  
      
  4 100 µM 0          <1.0 X 10-
7  
     0.03 X 10-
6
± 0.05×10
-6
 
 
Luteolin 1 75 µM  0          <1.0 X 10-
7
 
  2 100 µM 0          <1.0 X 10-
7
 
  3 175 µM 0          <1.0 X 10-
7
 
  4 200 µM 1          1.0 X 10-
7  
      
  5 200 µM 0          <1.0 X 10-
7
 
  6 200 µM 0          <1.0 X 10-
7
      0.03 X 10-
6
± 0.05×10
-6
 
     
MAG32A cell line was treated with various topo II inhibitors. 10
7
 cells were treated in 
each experiment. 
* The interchromsomal recombination and translocation frequency was calculated as the 
number of GFP+ clones per number of treated cells.  
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The relative frequencies of the appearance of GFP+ colonies from table 4 are 
plotted below in the form of a bar chart. It is noteworthy that genistein and quercetin are 
the most potent promoters of MLL-AF9 translocations. Benzoquinone, which is 
associated with non-MLL-rearranged leukemias, and dipyone, which is not a known topo 
II inhibitor generated none and one GFP+ colonies respectively at a high dose. Both these 
compounds are believed to have distinct mechanisms of action, different from the other 
topo II inhibitors used in this study. 
 
Figure 23: A bar chart representing the relative frequencies of appearance of GFP+ 
colonies upon treatment of MAG32A with various topo II inhibitors. 
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 A one-way ANOVA (comparing frequencies) was performed using Bonferroni 
post-hoc test. Both genistein and quercetin were significantly different from the untreated 
group, and both these compounds were also significantly different from benzoquinone, 
myricetin, dipyone and luteolin. 
Bioflavonoids genistein and quercetin (75 µM) were the most potent promoters of 
MLL-AF9 translocations in MAG reporter stem cell line. Treatment of stem cells with 
benzoquinone was not sufficient to produce MLL-AF9 translocations following exposure 
to concentrations up to 125 µM (frequency < 0.06 X 10
-6
). 
5.4 MAG68 generates GFP+ colonies at a lower frequency than MAG32A upon 
quercetin treatment 
 An independently generated reporter cell line MAG68 was treated with 75µM 
quercetin and GFP+ colonies were observed for this clone too, although at a lower 
frequency than for MAG32A. The comparative frequencies are provided in table 5. 
Table 5. Induction of interchromsomal recombination and translocations by quercetin 
between MLL and AF9 bcrs in MAG68 cell line: a comparison of frequency of GFP+ 
cells generated between MAG32A and MAG68. 
 
Compound Expt Dose         # GFP+         Frequency*             Average frequency 
            Colonies                  
 
Quercetin 1 75 µM  2         2.0 X 10-
7 
      
 
  2 75 µM  0         <1.0 X 10-
7
           1.0 X 10-
7
± 1.0×10
-7
 
  3 75 µM  1         1.0 X 10-
7 
      
 
     
MAG68 cell line was treated with 75 µM quercetin. 10
7
 cells were treated in each 
experiment. 
* The interchromsomal recombination and translocation frequency was calculated as the 
number of GFP+ clones per number of treated cells.  
 
MAG68 avg. frequency: 1.0 X 10-
7
± 1.0×10
-7
 
MAG32A avg. frequency: 1.1 X 10-
6
± 0.3×10
-6 
(Table 4) 
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The following figure 24 shows the relative frequencies of appearance of GFP+ 
colonies between MAG32A and MAG68 upon treatment with quercetin. 
 
Figure 24: A bar chart representing the relative frequencies of appearance of GFP+ 
colonies upon treatment with quercetin between MAG32A and MAG68. 
 
 
The frequencies were analyzed using a two-way ANOVA statistical analysis (both 
groups compared to untreated, and compared to each other) and Bonferroni post-hoc test. 
GFP+ frequencies for both MAG32A and MAG68 were statistically significant as 
compared to untreated and compared to each other. 
5.5 GFP+ cells are generated in a dose-dependent manner upon treatment of MAG32 by 
etoposide as detected by FACS  
Since no viable green fluorescent colonies could be obtained after etoposide 
treatment due to extensive cell death, fluorescence activated cell sorting (FACS) was 
performed on the etoposide treated MAG 32 cells as another approach to identify and 
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quantify GFP+ cells. This is a highly sensitive procedure and is able to sort individual 
GFP+ cells. GFP+ cells were sorted onto 96 well plates and expanded. They were 
observed each day. The frequency of GFP+ cells sorted by FACS after exposure to 
etoposide increased in a dose-dependent manner (figure 25). 
 
Figure 25: Etoposide exposure promotes MLL-AF9 repair events detectable as GFP+ cells   
FACS data of etoposide treated MAG 32 cells sorted for GFP+ cells. (a) Frequency of 
GFP+ MAG 32 cells treated with 50 µM etoposide is 0.017% (b) Frequency of GFP+ 
MAG 32 cells treated with 100 µM etoposide is 0.02% (c) Frequency of GFP+ MAG 32 
cells treated with 200 µM etoposide is 0.027% 
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The following table shows the frequency of GFP+ events sorted by FACS. 
Table 6. Induction of interchromsomal recombination and translocations by etoposide 
between MLL and AF9 bcrs in MAG32 cell line: Comparison between immediate events 
and long-term viable and proliferating events. 
 
Expt  Etoposide           # GFP+           # GFP+ cells 
 Dose  # cells  cells       Frequency *       proliferate  Frequency ^ 
 
1 50 µM  2.5×10
7
 0        < 4.0×10
-8
 0 < 4.0×10
-8
 
100 µM 2.0×10
7
 180           9.0×10
-6
  0 < 5.0×10
-8
 
200 µM 1.5×10
7
 305         20.3×10
-6  0 < 6.6×10-8 
2 50 µM  2.9×10
7
 480         16.6×10
-6  
3    0.10×10
-6
 
 
100 µM 3.0×10
7
 180           6.0×10
-6
  3    0.10×10
-6
  
200 µM 3.9×10
7
 420         10.1×10
-6  
15    0.36×10
-6
 
3 50 µM  9.8×10
6
 20           2.0×10
-6
  0 < 0.10×10
-6
  
100 µM 1.2×10
7
 10           0.8×10
-6
  3    0.24×10
-6
  
200 µM 8.3×10
6
 10                   1.2×10
-6
 3    0.36×10
-6
 
     
     Avg. 50 µM    6.2×10
-6
± 9.0×10
-6
     <0.08×10
-6
± 0.03×10
-6
 
    Avg. 100 µM               5.2×10
-6
± 4.1×10
-6
 <1.7×10
-6
± 2.8×10
-6
 
    Avg. 200 µM              10.5×10
-6
± 9.5×10
-6
       2.4×10
-6
± 3.6×10
-6
 
 
MAG32 cell line was electroporated with the I-SceI endonuclease expression vector 
pCBASce. 96 hrs post-electroporation, cells were analyzed by FACS.  GFP+ fluorescent 
cells were single-cell sorted into 96 well plates and cultured for XX days post-sort. 
* The initial interchromsomal recombination and translocation frequency was calculated 
as the number of GFP+ cells detected by FACS per number of cells analyzed by FACS.  
^ The long-term viable and proliferating interchromsomal recombination and 
translocation frequency was calculated as the number of GFP+ sorted cells that 
proliferated over time per the number of cells initially sorted as a fraction of the initially 
sorted GFP+ calculated frequency.  
 
 
 In spite of detecting GFP+ cells by flow cytometry, I could not see any viable 
green fluorescent colonies under the microscope upon treatment of reporter cell lines by 
various doses of etoposide. This could be possible due to etoposide being severely lethal 
to the cells. Due to the high genotoxicity associated with etoposide treatment, it is 
possible that the colonies that undergo MLL-AF9 translocations are relatively impaired in 
cell division and are outcompeted by other healthier wild type cells. This results in their 
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not producing enough green fluorescent cells to be detectable by microscopy. Since 
FACS is much more sensitive in detection of fluorescence from even a single cell, I was 
able to detect and sort those green fluorescent cells which probably could not produce 
colonies on a culture dish. 
 However, these etoposide-treated cells were not allowed to proliferate long term 
in an LTC-IC (long-term culture initiating cell) assay as has been discussed in previous 
studies (Libura, Ward et al. 2008). It is possible that these green fluorescent cells that 
were detected by FACS would have proliferated to form colonies if I had performed an 
LTC-IC assay on these plates. 
5.6 Conclusion 
 In this chapter I have described the quantification of GFP+ colonies after treating 
the reporter cell lines with varying doses of different topo II inhibitors including the 
chemotherapeutic drug etoposide and different bioflavonoid compounds. The results 
include comparison of frequencies of appearance of GFP+ colonies among three different 
and independently obtained reporter cell lines and among the different compounds used. 
  
 
 
 
 
 
CHAPTER 6: DISCUSSION AND FUTURE DIRECTION  
 
 
 In this thesis I have demonstrated that MLL and AF9 bcrs undergo DSBs, and are 
highly recombinogenic independent of normal chromosomal context, and in the absence 
of a leukemic fusion protein; and a number of topo II inhibitors have the potential to 
promote these translocations analogous to those observed in infant leukemia. In addition, 
this reporter gene system allows for rapid and reproducible screening of hundreds of 
compounds that may have the potential to promote leukemogenic translocations. The 
results shown here above provide the first direct evidence of induction of DSBs and 
translocations by dietary compounds and nutritional supplements that act as topo II 
inhibitors. 
 These bioflavonoids have been shown to inhibit topo II in in vitro DNA cleavage 
assays of the MLL gene (Schroder-van der Elst, van der Heide et al. 1998, Strick, Strissel 
et al. 2000, Bandele and Osheroff 2007, Barjesteh van Waalwijk van Doorn-Khosrovani, 
Janssen et al. 2007, Bandele and Osheroff 2008, Azarova, Lin et al. 2010, Kalfalah, 
Mielke et al. 2011, Vanhees, de Bock et al. 2011). Unregulated use of these bioflavonoids 
as nutritional supplements may prove to be harmful, and their potential to promote 
leukemic translocations should be determined.  
 To determine the potential of topo II inhibitors such as etoposide to lead to MLL 
rearrangements, in vitro studies have been performed using inverse polymerase chain 
reaction (IPCR) to characterize the resultant MLL repair products following exposure to 
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etoposide. This technique has been used to detect alterations to the MLL translocation 
hotspot region (Bernard and Berger 1995, Reichel, Gillert et al. 2001, Rowley and Olney 
2002, Whitmarsh, Saginario et al. 2003, Blanco, Edick et al. 2004, Libura, Slater et al. 
2005). However this approach requires the elimination of artifacts such as ligation of the 
target DNA fragment with other fragments, inefficient amplification of large digested 
fragments, less physiologically relevant internal deletions or intronic alterations from 
analysis. This approach also does not allow for the clonal expansion of the cells 
containing a particular translocation/rearrangement event. A genetic system to directly 
and rapidly examine the role of different compounds in promoting these specific genome 
rearrangements has been lacking. I demonstrate here the sensitivity of the MLL and AF9 
bcrs to topo II poisons and bioflavonoids independent of their normal chromatin context 
and independent of the formation of a leukemic fusion protein. This genetic assay does 
not rely on IPCR that requires elimination of artifacts or less physiologically relevant 
internal deletions or intronic alterations from analysis. 
6.1 Influence of Chromsomal Context: 
1) Context-independent recombinatorial potential of MLL and AF9 bcrs  
 These results have demonstrated the significant recombinatorial potential or 
sensitivity of the two bcr regions to these compounds independent of their normal 
chromosomal context. My system generated recombination leading to translocations 
between human MLL and AF9 bcrs following their random and independent integration 
into the mouse genome. The MLL bcr is AT rich and contains repetitive Alu elements 
which have been shown to play a role in promoting the rearrangements in this region 
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even when taken out of their normal context (Elliott, Richardson et al. 2005, Libura, 
Slater et al. 2005). 
The DSBs created in the MLL and AF9 GFP reporter constructs were sufficient by 
themselves to result in aberrant NHEJ repair and translocations in the cells. The 
formation of translocations and stable viable GFP+ colonies in this system did not require 
the presence of a pre-existing mutation or another protein factor only expressed in more 
differentiated cell types. Expression of the restored exon resulted in GFP+ cells in all 
three MAG clones (Figure 13). Overall, these experiments with these cell lines 
demonstrate that aberrant NHEJ repair of the MLL bcr construct with the AF9 bcr 
construct to produce translocations occur independently of the normal chromosomal 
context.  
2) Influence of integration site and chromosomal context on the rate of recombination 
between MLL and AF9 bcrs 
We observed variation in the frequencies of GFP+ cells generated among 
different independently created reporter cell lines. The frequency of appearance of GFP+ 
colonies generated in the MAG 68 cell line after both ISceI expression and quercetin 
treatment was consistently lower than the frequencies observed in MAG32A (Table 5). A 
possible explanation for this is that the MAG 32A and MAG 68 cell lines have the MLL 
and AF9 bcr constructs integrated into the genome at different chromosomal locations. 
This trend suggests that chromosomal context can lead to very subtle differences. 
Alternatively, other characteristics of MAG 68 may lead to reduced fitness and increased 
length of the cell cycle. Such differences could result in generation of smaller colonies or 
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non-proliferating colonies that were not observable by microscopy although such a 
difference would be small since many colonies were readily detected.  
 In another independently obtained reporter cell line (MAG60) (Table 1), I did not 
see the generation of any GFP+ colonies even though the presence of MLL and AF9 
transgenes were confirmed by Southern blotting. This could have occurred due to two 
possibilities. 
1) The two GFP reporter constructs may have integrated in separate chromosome 
domains which do not or rarely intermingle (Visser and Aten 1999). These could 
be regions of heterochromatin which do not undergo breakage easily. 
2) The integration of the MLL and AF9 GFP reporter constructs may have possibly 
occurred in heterochromatin where there is low or no transcription. Even if a 
translocation occurred, the fusion gene formed as a result of translocations may 
have never been expressed leading to no GFP expression. In the future, a next step 
could be to target these reporter transgene constructs to specific sites in the 
genome to address these problems. However, this reporter gene system provides 
valuable data on MLL-AF9 translocations that occur independent of the context 
and the site of insertion of these constructs into the genome. 
6.2 Comparative genotoxicity and mechanisms of action of compounds used in the study 
 The reporter mouse embryonic stem cells were treated with etoposide, quercetin, 
genistein, luteolin, dipyrone, myricetin or benzoquinone, then allowed to repair and 
proliferate in culture. GFP+ fluorescent colonies indicative of MLL-AF9 bcr 
translocations were readily scorable by 96 hours in a dose-dependent manner.  
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 As previously demonstrated (Libura, Slater et al. 2005), embryonic stem cell 
viability was significantly impaired by multiple concentrations of etoposide. My results 
show that etoposide treatment is sufficient to result in formation of translocations 
between the two bcrs, and the frequency is dose dependent. Three different doses of 
etoposide were used in FACS analysis (Figure 25) (Libura, Ward et al. 2008). The dosage 
corresponds to the physiologically relevant dosage administered to patients during 
chemotherapy (Libura, Slater et al. 2005, Goodman, Gilman et al. 2008).  
 My results demonstrate the sensitivity of mouse embryonic stem cells to these 
compounds that are topoII inhibitors. The chemotherapeutic drug etoposide is the most 
toxic to cells, and the cells also exhibit considerable sensitivity to bioflavonoids genistein 
and quercetin, whereas luteolin seems to moderately affect the cells (Figure 20). 
 Genistein and quercetin were potent promoters of MLL-AF9 translocations in 
totipotent reporter stem cells in this genetic assay. It is noteworthy that GFP+  colonies 
were obtained after treatment with the bioflavonoids genistein and quercetin which have 
been hypothesized as being topo II inhibitors but have not yet been shown to directly 
promote translocations that involve the MLL gene (Bandele and Osheroff 2007). These 
results for the first time provide insight into the interplay between topo II poisons, topo II 
cleavage and religation, and the resulting DNA damage and translocations analogous to 
those observed in human leukemia samples.   
The bioflavonoids genistein, quercetin, luteolin and myricetin are shown here for 
the first time to induce such leukemogenic translocations. The frequency is dose-
dependent and can easily be quantified. However, myricetin and luteolin were much less 
potent than genistein and quercetin, and luteolin only gave one GFP+ clone at a high dose 
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of 200 µM (see table 4). These results could be explained based on the observations that 
different topo II inhibitors differ in their interaction mechanisms with the enzyme topo II. 
Different topo II poisons have been shown to have different sequence specificity in vitro 
e.g. clerocidin requires a guanine, VM-26 a cytosine, and dh-EPI a 5’-TA dinucleotide, 
respectively, at the 3’ terminus of DNA break generated by topo II (Borgnetto, Tinelli et 
al. 1999). Also, clinical studies have shown that different chemotherapeutic agents 
predispose patients to different translocations associated with leukemias (Mistry, Felix et 
al. 2005). 
6.3 Benzoquinone and dipyrone act through a different mechanism  
The significance of this reporter system is apparent from treatment of stem cells 
with benzoquinone that was not sufficient to promote MLL-AF9 bcr translocations 
following exposure to concentrations up to 125 µM. Benzoquinone is a non-bioflavonoid 
thought to have a distinct mechanism of action and is clinically associated with non-
MLL-rearranged leukemias. Benzene is carcinogenic and causes primarily hematopoietic 
cancers in humans. It has been reported that it causes DNA damage through its 
metabolites, especially 1,4-benzoquinone. 1,4 benzoquinone is a strong topo II poison in 
vitro as has been shown using purified human topo IIα in a plasmid DNA cleavage 
assay(Lindsey, Bromberg et al. 2004). However, it has not been shown to induce 
rearrangements of the MLL bcr. It is noteworthy that in spite of benzoquinone being a 
topo II inhibitor, I did not observe any MLL bcr translocations induced by it, suggesting 
that it causes other genomic rearrangements by topo II inhibition, and is not associated 
with MLL-rearranged leukemias. 
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Maternal use of dipyrone during pregnancy has been shown to be associated with 
infant acute leukemia (IAL) in a hospital-based case-control study conducted in different 
cities of Brazil (Pombo-de-Oliveira, Koifman et al. 2006). Dipyrone is not a known 
topoII inhibitor but is implicated as an increasing risk in infant acute leukemia. I could 
observe only one GFP+ colony upon treatment with dipyrone in this reporter gene system 
at a high dose of 100 µM (frequency 0.03 X 10-6), which correlates with the fact that it 
possibly acts through a different mechanism and does not inhibit topo II.  In countries 
such as Bulgaria, Chile, China, Egypt etc, it is one of the most popular analgesics. 
However, it was banned in the US in 1977. 
6.4 DNA Repair Mechanisms that could be involved in the generation of reporter GFP+ 
colonies 
 The two major pathways of DSB repair are HR and NHEJ. As discussed in the 
introduction, extensive work with ISceI model systems has demonstrated that HR or a 
combination of HR and NHEJ can lead to genome instability and chromosomal 
translocations. However, sequencing of breakpoint junction DNA from translocations 
between the MLL and AF9 bcrs in patients with t-MDS or t-AML suggests that they arise 
from aberrant NHEJ repair of DNA DSBs between the two broken duplexes (Harper and 
Aplan 2008). It is known that DSBs can be induced by a variety of agents including topo 
II poisons, suggesting that the previous treatment regimens with these poisons can induce 
the translocations to form that lead to t-MDS and t-AML (Azarova, Lyu et al. 2007). 
However, it is also possible that the translocations occur in these patients by a different 
mechanism altogether, or that the creation of the translocations only happens in cells 
already mutant in other genes making them predisposed to this event.  
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 Thus this genetic system was created to specifically mimic the aberrant repair that 
leads to MLL and AF9 translocation reported in clinical samples. The focus of this project 
is to directly determine if DSBs created in the MLL and AF9 bcrs analogous to those seen 
in patient samples are sufficient to produce translocations in mouse EtG2a ES cells. In 
this thesis, I have shown for the first time that these compounds are sufficient to directly 
induce MLL and AF9 translocations as have been observed in the clinical setting in wild 
type cells that do not harbor any other mutations. Molecular analysis of the breakpoint 
junctions cloned in the GFP+ cells generated by these compounds is being performed in 
our lab. However, I showed in a GFP+ clone generated in this reporter system by the 
expression of endonuclease I-SceI that the GFP gene was reconstituted due to an aberrant 
NHEJ repair of the DNA DSBs created in the MLL and AF9 bcrs at the ISceI restriction 
sites (Figure 17). This is a relatively more controlled system as compared to inducing 
several DSBs in the same system when topo II inhibitors are used.  
 DSBs were created by the use of the highly specific ISceI endonuclease, a known 
topo II poison etoposide, certain bioflavonoids, the non-steroidal anti-inflammatory drug, 
dipyrone and the benzene metabolite benzoquinone. The etoposide dosage used 
corresponds to the physiologically relevant dosage administered to patients during 
chemotherapy (Libura, Slater et al. 2005, Goodman, Gilman et al. 2008). The doses for 
the other compounds were determined from previous studies and also determined from 
the cell viability plots obtained for these compounds (Figures 18, 19 and 20). 
 Translocation events could be identified by the fusion of GFP reporters 
specifically designed for this system. Translocation events, as a result of NHEJ, brought 
together the 5’ GFP and 3’ GFP exons as a functional intron containing gene (Figure 13). 
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Transcription, splicing and protein expression led to the expression of the restored GFP 
gene, resulting in GFP+ cells (Figures 21 and 22) (Tables 4 and 5). NHEJ DNA repair is 
hypothesized to occur, since it is the predominant mechanism of DSB repair in 
mammalian cells in the G1 phase of the cell cycle (Rothkamm, Kuhne et al. 2001). 
Sequencing of the breakpoint junction from a GFP+ clone produced by ISceI 
endonuclease in the reporter cell line MAG 32A also indicates NHEJ as the mechanism 
(Figure 17). 
6.5 Possible alternative events not leading to the generation of a GFP+ cell  
 This system was designed to specifically detect and quantify NHEJ mediated 
translocations between MLL and AF9 bcrs. Generation of a GFP+ fluorescent colony is a 
simple and readily identifiable readout for these events. I acknowledge that there are 
multiple additional events that may have occurred during repair of the DSBs that would 
not produce a GFP+ cell. However, overall these events would also not be expected to 
lead to a stable chromosomal translocation in a viable cell capable of continued long-term 
proliferation; thus, their occurrence would not necessarily be relevant to the questions 
that I addressed. 
 Firstly, there is a possibility that the DNA repair between the DSBs created at the 
MLL and AF9 GFP reporter constructs had DSB end resection that continued to remove 
nucleotides so that the splice donor site and/or the splice acceptor site in the 5’ and 3’ 
GFP exons were lost (Figure 13). The Artemis:DNA-PKcs complex during NHEJ repair 
can endonucleolytically cut overhangs (Ma, Schwarz et al. 2005, Yannone, Khan et al. 
2008). The average nucleolytic resection from each DNA end varies from 4 to 14 bp, but 
there are cases of resections up to ~25 bp (Gauss and Lieber 1996, Lieber 2010). The 
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resection at the break sites may have continued into the GFP exons, removing 
nucleotides. Expression of the restored GFP exon may have resulted in a mutant or 
truncated protein which cannot function properly and result in green fluorescent cells. For 
compounds that do not produce any GFP+ cells or give a very low frequency of such 
cells, an alternative approach could be to screen several randomly picked colonies by 
PCR using primers specific for the MLL and AF9 bcrs to pick any translocation that may 
have deleted parts of the GFP exon. New techniques are available where it is possible to 
extract DNA from single cells or very few cells and use it for PCR after whole genome 
amplification.  
 Secondly, there is a possibility that the breaks created were repaired without loss 
or gain of nucleotides to reform a viable I-SceI site. Continued expression of the 
pCBASce plasmid may have resulted in the DSB being formed and religated through 
repair. The I-SceI community has grappled with this issue for over a decade. However, 
these continued breaks are not physiologically significant, therefore the use of topo II 
inhibitors in this study is an even more relevant approach to investigate the kind of DNA 
damage that cells are exposed to that can lead to leukemogenic translocations. 
 Thirdly, the DSBs created may have been repaired by NHEJ (Gauss and Lieber 
1996, Lieber 2010) independently of each other thus not generating a translocation or 
generating a GFP+ gene. Such an event is known to be significant and occur more 
frequently than an aberrant repair in wild type cells as well. The DSBs that are induced in 
a cell after exposure to DNA damaging agents lead to translocations in some cases, but in 
other cases they are normally repaired. So, the frequencies that we obtain are 
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representative of the net potential of these compounds to lead to aberrant DNA repair 
after DSB induction. 
 Fourthly, there is a possibility that DSB induction may have triggered a cell cycle 
arrest and have resulted in apoptosis and cell death due to the presence of multiple DSBs 
all over the genome. They may not have been able to divide and form colonies to be seen 
under a microscope. To determine the toxicity of each compound, I performed cell 
viability assays (Figures 18, 19 and 20). In addition, I noted cell death visually on plates 
as evidenced by colonies rounding up and detaching from the plates, although I did not 
definitively distinguish between the different pathways leading to cell death (apoptosis vs 
necrosis). There are staining procedures like TUNEL assay that can be performed to scan 
and visualize the apoptotic colonies on a plate that has been treated with a topo II 
inhibitor. However, apoptotic cells will not lead to and propagate a genome 
rearrangement and thus will not contribute to any leukemogenic translocations. If a cell 
harboring a translocation does not proliferate in culture and is not able to divide and form 
more cells harboring the same mutation, it probably does not have the potential to lead to 
leukemia. Therefore, this possibility does not affect the conclusions from this reporter 
system. No GFP+ colonies could be seen under the microscope after etoposide treatment 
possibly due to the high toxicity of this drug to the cells after acute treatment. 
 FACS was performed on the etoposide-treated cells to identify GFP+ cells. 
Etoposide was shown to generate GFP+ cells with a dose-dependent increase in 
frequency. FACS is a highly sensitive procedure capable of sorting individual GFP+ cells 
to provide a much more accurate identification of GFP+ cells as compared to scanning 
under a microscope by human eye using a fluorescent filter. Not all of the sorted cells 
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survived, as shown in (Table 6). There are two possibilities for the low survival rate. 
Firstly, the cells may not have been able to survive the FACS procedure and the stress it 
puts upon the cells. Secondly, DSB repair by NHEJ resulting in translocations may have 
caused the cells to become unstable, thereby undergoing apoptosis. The cells that did 
survive the sort were expanded and used to isolate their genomic DNA for future 
experiments.  
 The low number of GFP+ cells and colonies, isolated by FACS as well as 
scanning under the microscope, may be due to the possibility that the initial number of 
cells treated with etoposide was low. We did increase the number of cells treated with 
etoposide, but were not able to isolate or observe any live colonies that were GFP+. In the 
future, using low doses of etoposide in chronic exposure rather than an acute exposure for 
1 hour may lead to survival of some GFP+ colonies. 
6.6 Further molecular analysis of the repair products from GFP+ reporter colonies  
 DNA from expanded as well as sorted GFP+ clones isolated may be used for 
further molecular analysis including PCR sequencing across the breakpoint junctions. 
Several GFP+ colonies were picked and expanded after ISceI expression and treatment 
with the other compounds (Tables 3, 4 and 5). DNA from one GFP+ clone obtained after 
ISceI expression was sequenced and shown to possibly undergo NHEJ at the repair 
junction (Figure 17). In addition, metaphase spreads of the GFP+ clones can be sent for 
spectral karyotyping (SKY) that labels each chromosome with a unique fluorescent color 
which can be used to identify chromosomal translocations at the karyotypic level. This 
will provide more data and specific details about the type of DNA repair mechanism used 
to repair the induced DSBs.  
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6.7 Significance and future direction 
 I have successfully demonstrated the sensitivity of the MLL and AF9 bcrs to topo 
II poisons and bioflavonoids independent of their normal chromatin context and 
independent of formation of a leukemic fusion protein. In addition, the reporter system 
allows for rapid and reproducible screening of hundreds of compounds that may have the 
potential to promote leukemogenic translocations in early stem cell and more 
differentiated cell subpopulations analogous to the events observed in infant acute 
leukemias. A wide variety of dietary compounds are being consumed and recommended 
widely for their presumed health benefits. This is a great system to allow for rapid 
screening of all those compounds and assess the potential risks associated with their 
unregulated use and in the development of infant leukemia due to maternal consumption 
of these compounds. All of these compounds can be quickly screened and the frequency 
of leukemogenic translocations induced by them can be readily assessed. 
ISceI induction led to the appearance of green fluorescent cells due to induction 
of DSBs in the bcrs, whereas the negative (no DNA or empty vector) controls did not 
generate any GFP+ colonies. 
In parallel with experiments with the reporter clone MAG 68, a control cell line 
(F2) that did not show the presence of both MLL and AF9 transgenes by Southern 
blotting was also treated with ISceI or topo II inhibitors. By contrast with results with 
clone MAG68, F2 did not lead to any detectable GFP+ colonies by microscopy after any 
treatment. These results are consistent with the idea that GFP+ colonies detected in this 
system are specific to DSBs and the generation of translocations rather than background 
fluorescence.  
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This approach has several advantages over the use of IPCR in in vitro studies to 
study MLL rearrangements after exposure to topo II inhibitors. IPCR requires the 
elimination of artifacts such as ligation of the target DNA fragment with other fragments, 
inefficient amplification of large digested fragments, less physiologically relevant 
internal deletions or intronic alterations from analysis. 
In the future, it would be significant to determine the frequency of translocations 
on combined treatment/exposure to multiple topo II inhibitors to investigate the effect of 
analogous combinatorial treatment with these compounds during chemotherapy and 
exposure to multiple bioflavonoids in the diet. Any increase/alterations to the frequencies 
on such combined exposure will provide great insights in to the possible risk due to the 
synergistic effect of these compounds on DNA repair mechanisms. 
The next step would be to modify this system for in vivo analysis and generate 
mice that contain these reporter transgenes in their genome. Direct exposure of these 
mice to these compounds or their combinations would be the most physiologically 
relevant and informative model of an assessment of the risk of genome rearrangements 
due to human consumption/exposure of these compounds. The physiological aspects that 
can be studied in mice are drug clearance, absorption, any tissue- or cell type- specific 
differences in chromosomal rearrangements, and influence of the genetic background of 
mice. Stem cells proliferate highly in culture, which could be different from how they 
respond in mice. Developmental programming and in utero exposure to these compounds 
can also lead to long-term genetic and epigenetic changes (see appendix). In addition, 
bioflavonoids genistein and quercetin have also been shown to produce MLL 
rearrangements by IPCR in mice (Vanhees, de Bock et al. 2011). However, IPCR 
79 
 
 
requires elimination of artifacts or less physiologically relevant internal deletions or 
intronic alterations from analysis, and hence is not a reliable and valid technique to 
investigate rearrangements. 
 The use of the environmental, dietary and therapeutic agents is widespread today. 
Increasing evidence is emerging regarding the long-term implications and adverse effects 
of using these compounds in an unrestricted manner. Due to the beneficial effects 
assumed to be associated with the use of bioflavonoids, their use as dietary supplements 
is popular and widespread. The cytotoxic and genotoxic properties of all the agents 
discussed above have so far generally been ignored as far as their use for various 
purposes is concerned. In view of the variety of adverse effects these agents have in 
exposed individuals and the transgenerational nature of these effects, it is important to 
raise public awareness, set guidelines and regulate the use and market availability of such 
compounds to reduce the risk of human disease. 
 Since the role of in utero exposures in causing long-term transgenerational effects 
has been demonstrated to be critical, it is important to address the susceptibility of 
different stages of cell differentiation to the deleterious molecular changes induced by 
these agents. Using my developed model system for cells at different stages of 
differentiation with different susceptibility to genomic damage and repair will provide 
useful insights into the comparative risk to the human population in terms of the different 
windows where exposure occurs. 
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Abstract 
The presence of histones acts as a barrier to protein access, and chromatin remodeling 
must occur for essential processes such as transcription and replication. In conjunction 
with histone modifications, DNA methylation plays critical roles in gene silencing 
through chromatin remodeling. Chromatin remodeling is also inter-connected with the 
DNA damage response, maintenance of stem cell properties, and cell differentiation 
programs. Increasingly, chromatin modifications are shown to produce long-lasting 
alterations in chromatin structure and transcription. Recent studies have shown 
environmental exposures in utero have the potential to alter normal developmental 
signaling networks, physiologic responses, and disease susceptibility later in life in a 
process known as developmental reprogramming. In this review we will discuss long-
term impact of exposure to environmental compounds, chromatin modifications that they 
induce, and the differentiation and developmental programs of multiple stem and 
progenitor cell types altered by exposure. The main focus is to highlight the variety of 
agents present in the human lifestyle that have the potential to promote epigenetic 
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changes that impact developmental programs of specific cell types, and may be 
transgenerational, e.g. able to be transmitted through multiple cell divisions. 
 
 
1.  Introduction 
 
1.1 Chromatin remodeling and epigenetics 
 
Epigenetics is the study of heritable changes in gene expression without a change in the 
DNA sequence. Nucleosomes are composed of 147 bp of DNA wrapped around core 
histone proteins H2A, H2B, H3, and H4. Histone H1 acts to link histones together and 
also to the nuclear scaffold. H3 and H4 termini extend out from the nucleosome and can 
be modified chemically by acetylation, methylation, ubiquitination, phosphorylation, 
sumoylation, citrullination, and ADP-ribosylation [1]. Modifications promote either open 
or closed chromatin which in turn influences multiple cellular processes transcription and 
replication. Chromatin remodeling is also inter-connected with the DNA damage 
response, maintenance of stem cell properties, and cell differentiation programs. Patterns 
of histone modifications are maintained after replication and thus inherited through 
multiple cellular generations. DNA methylation predominantly involves the covalent 
addition of a methyl group (CH3) to cytosine in the context of CpG in DNA. DNA 
methylation is a significant epigenetic mark of transcriptional inactivity, Patterns of DNA 
methylation are generated during development involving de novo methylation and 
demethylation mediated by DNA methyltransferases (DNMTs). DNMT3 regulates de 
novo methylation during development, and DNMT1 maintains DNA methylation patterns 
following replication. Global genome methylation patterns are highly developmental 
stage- and tissue-specific. 
Recent literature demonstrates that commonly used dietary, environmental, and 
therapeutic compounds have the potential to induce both DNA genomic and also 
epigenetic modifications. Exposure to these agents can induce epigenetic alterations by 
histone modification, changes in cell differentiation, modulation of cellular signal 
transduction pathways including DNA damage repair pathways, changes in gene 
expression, illegitimate DNA repair leading to genome rearrangements and 
carcinogenesis. Recently, multiple lines of evidence through in vitro and in vivo studies 
have shown that in utero exposure to environmental toxicants can cause epigenetic 
modifications which in turn induce alterations in gene expression that persist throughout 
life [1, 2]. 
 
1.2 The connection between epigenetic alterations and DNA double-strand breaks  
 
The DNA double-strand break response (DDR) is facilitated by hierarchical signaling 
networks that orchestrate chromatin structural changes, cell cycle checkpoints, and 
multiple enzymatic activities to repair the broken DNA ends. DNA double-strand breaks 
(DSBs) have the highest potential to promote illegitimate repair mechanisms, 
accumulation of mutations, and are considered the critical primary lesions in the 
formation of chromosomal rearrangements associated with disease and tumorigenesis.  
The recent advances in the understanding of the interplay between chromatin remodeling, 
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epigenetics, and DDR have been reviewed [3-5]. New emerging evidence extends earlier 
findings with the potentially pathological repercussions of restoration of chromatin 
structure resulting in a DSB-induced epigenetic memory of damage.  
Chromatin dynamics and changes in chromatin architecture that occur for repair of DSBs 
include nucleosome eviction from DSBs, relaxation of heterochromatin structure, and 
localized chromatin destabilization at DSBs [6]. After DNA damage, chromatin structure 
is altered by ATP-dependent chromatin remodeling, incorporation of histone variants into 
nucleosomes, and covalent histone modifications. These histone modifications include 
phosphorylation of H1; acetylation of H2A, phosphorylation and ubiquitination of 
H2AX; acetylation and methylation of H3; and phosphorylation and acetylation of H4. 
Among the different histone modifications, phosphorylation of all four histones as well as 
the variant H2AX plays a primary role in DNA damage response by facilitating access of 
repair proteins to DNA breaks. Phosphorylation of histone variant H2AX (γH2AX) 
spreads over large chromatin domains from a DSB. This chromatin marking and large-
scale chromatin reorganization recruits repair factors, recombination proteins and 
chromatin remodeling complexes involved in DNA repair pathways.  
Heterochromatin is the tightly compacted DNA structure that acts as a barrier for DNA 
repair processes. As a result, heterochromatic DSBs are generally repaired more slowly 
than euchromatic DSBs [7], and heterochromatin and euchromatin utilize distinct 
remodeling complexes and pathways for DSB repair. DSB repair may be stalled within 
HC regions if a series of dynamic and localized changes fail to take place. The ataxia 
telangiectasia mutated (ATM) protein and DDR mediator proteins overcome constraints 
posed by heterochromatin superstructure to promote repair through modulation of two 
HC factors -- KAP-1 co-repressor and HP1 chromodomain protein [8]. Activation of the 
ATM signaling pathway and the subsequent phosphorylation of KAP-1 trigger HC 
modifications required for DSB-repair. In addition, studies have shown that histone 
acetyl transferase (HAT) complexes act with the ATP-dependent SWI/SNF and RSC-
containing chromatin remodeling complexes to facilitate DNA repair [9]. 
Polycomb group (PcG) proteins, which have well-established roles in gene regulation, 
were recently found to accumulate on chromatin surrounding DNA damage [10]. PcG 
proteins are a family of proteins that form complexes involved in the epigenetic 
regulation of gene expression. Ploycomb repressive complexes catalyze post-translational 
modifications critical to their gene silencing function, including histone H3K27 
trimethylation  (H3K27me3) and histone H2A ubiquitination. This complex may also be 
involved in DNA methylation. PcG and PRC components found to respond to DNA 
damage include BMI-1, MEL-18, EZH2 methyltransferase, EZH1, EED, SUZ12. Gene 
silencing activity of PcG proteins, like mono-ubiquitylation of H2A is exploited during 
DSB repair. 
Several chromatin-remodeling factors form a complex with DDR-related proteins in 
response to DNA damage. Scaffold matrix attachment region 1 (SMAR1) binds other 
SMAR1 elements along with histone deacetylase 1 (HDAC1) and p53, forming a 
repressor complex to downregulate transcription. The chromatin-remodeling factor Tip49 
recruits Rad51, the homolog of bacterial RecA and major homologous recombination 
repair protein, to DNA damage sites. Signal transduction pathways in DDR communicate 
with chromatin-remodeling factors. In addition to DNA repair, the p53 signaling pathway 
is associated with chromatin changes that mainly involve the HAT Tip60. Numerous 
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chromatin-remodeling factors that are involved in DNA methylation and demethylation 
also play a role in DDR. In the thymus, genotoxic stress exposure decreases DNA 
methylation globally by a reduction in DNMT1, DNMT3a, DNMT3b and methyl-binding 
proteins MeCP2 and MBD2.  
 
2. Environmental Toxins 
 
2.1 Alcohols and Aldehydes 
 
There is sufficient evidence in the literature demonstrating the genotoxic effects of 
aldehydes on cells. Aldehydes produced endogenously have also been found to have 
genotoxic effects. Reactive aldehydes, such as acetaldehyde, are by-products of 
metabolism. Bone marrow failure in Fanconi anemia may result in part from aldehyde-
mediated genotoxicity in the hematopoietic stem and progenitor cell pool. Mouse 
hematopoietic stem and progenitor cells are more susceptible to acetaldehyde toxicity as 
compared to mature blood precursors. Hematopoietic stem cells from Aldh2
-/-
 Fancd2
-/- 
mice that are deficient in the Fanconi anemia pathway-mediated DNA repair and in 
endogenous acetaldehyde detoxification undergo a > 600-fold reduction in numbers, 
display a predisposition to leukemia, and require Aldh2 for protection against 
acetaldehyde toxicity [11]. Another endogenous source of acetaldehyde is in the first 
product from breakdown of alcohol in cells. It has been previously proposed that 
acetaldehyde generated from alcohol metabolism reacts in cells to generate DNA lesions 
that form inter-strand crosslinks (ICLs) [12]. Since the Fanconi anemia-breast cancer 
associated (FANC-BRCA) DNA damage response network plays a crucial role in 
protecting cells against ICLs, Marietta et al. tested the proposed role of acetaldehyde in 
generating ICLs [13]. They exposed human lymphoblastoid cells from normal individuals, 
an XPA patient, an FA-G patient and an FA-A patient to acetaldehyde and studied the 
activation of the FANC-BRCA network. Their study reported that acetyladehyde in a 
dose range of 0.1 – 1 mM stimulates FANCD2 monoubiquitination, BRCA1 
phosphorylation at Ser1524, and γH2AX at Ser139 in a dose-dependent manner. These 
results demonstrate interplay between multiple DDR networks and may also support 
differential tissue specificity of alcohol-related carcinogenesis [13]. The data also support 
findings of alcohol and increased breast cancer risk. Chronic exposure to ethanol induces 
DNA damage and an induction in the levels of the Fanconi anemia D2 (FANCD) protein 
in both human neural precursor SH-SY5Y ccells in culture and in the midbrain of 
C57BL/6J mice in vivo [14]. FANCD2 response induced by alcohol thus plays a role in 
DDR in post-mitotic neurons and in neural precursor cells.  
Alterations in epigenetic marks induced by alcohols and aldehydes are linked with altered 
cellular differentiation. In cardiac progenitor cells, although low levels of ethanol, 
acetaldehyde, and acetate had no effect on the proliferation of cells, they did promote a 
>2-fold increase in histone H3K9 acetylation (H3K9ac). High concentrations sufficient to 
produce a 30% reduction in cell viability also increased H3K9ac by >5-fold. In addition, 
high concentrations significantly elevated the expression of GATA4 and Mef2c genes 
related to heart development, resulting in their impaired differentiation [15]. Consistent 
with these findings, the deregulation of genes that play a role in heart development has 
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been proposed to be one of the mechanisms for the occurrence of congenital heart disease 
due to alcohol exposure during pregnancy.  
Occupational and environmental exposures to formaldehyde are prevalent. Its production 
is carried out on a large scale in the manufacture of resins, particle board, plywood, 
leather goods, paper, and pharmaceuticals. Formaldehyde is known to have genotoxic and 
mutagenic potential. It has been demonstrated that formaldehyde induces genotoxicity by 
causing DNA-protein crosslinks. In addition, lysine residues in the N-terminal tail and the 
globular fold domain of histone have been identified as binding sites for formaldehyde in 
in vitro studies using purified calf thymus or human H4 [16]. The final concentration of 
formaldehyde varied from 5mM to 100 mM, and the reaction time ranged from 3 h to 2 
weeks [16]. This study also demonstrated that formaldehyde could inhibit post-
translational modifications on histone thereby affecting epigenetic regulation.  
 
2.2 Benzene and its metabolites 
 
Benzene is a ubiquitous pollutant and is one of the top production chemicals in the 
United States. It is used in the manufacturing industry and is a combustion product of 
cigarette smoke. Benzene is carcinogenic and causes primarily hematopoietic cancers in 
humans. It has been reported that it acts through its metabolites, especially 1,4-
benzoquinone (1,4 BQ), as a strong topoisomerase II poison causing DNA DSBs [17]. 25 
µM 1,4BQ in vitro stimulates DNA cleavage by topo II 8-fold at sites close to defined 
chromosome breakpoints in leukemia. Benzene metabolites 1,4-BQ (1-10 µM) or 1,4-HQ 
(10-100 µM) cause DNA damage and fragmentation in cultured HL60 cells though the 
generation of H2O2 oxidative stress leading to apoptosis [18]. Benzene and its metabolites 
including benzoquinone also influence the downstream DNA repair of DSBs. As little as 
1µM benzoquinone was sufficient to increase homologous recombination repair in a 
Chinese hamster ovary (CHO) cell line containing a neomycin gene direct repeat 
recombination substrate by 2.7-fold [19]  
Studies have extended earlier cell culture studies to in vivo mouse models showing 
alterations in epigenetic marks and developmental reprogramming. Neonatal exposure to 
1,4-bis[2-(3,5-dichloropyridyloxy)] benzene resulted in activation of constitutive 
androstane receptor (CAR) and a permanent increase of H3K4 mono-, di-, and 
trimethylation (H3K4me, H3K4me2, H3K4me3)  and decrease of H3K9 trimethylation 
(H3K9me3) within the Cyp2B10 locus [20]. These epigenetic changes were maintained 
in mice throughout life and resulted in a permanent change of liver drug metabolism [20]. 
Taken together, the in vitro and in vivo studies provide further support for the interplay 
between the DDR, DNA repair, and long-term chromatin remodeling. 
 
2.3 Metals 
 
Trace amounts of metallic compounds are pervasive in the environment. They are present 
in air, water, and food, and occupational exposure to them may occur through industrial 
production and waste disposal. Several studies have determined that trace metals cross 
the placenta [21-26], and presence of Cd, Cu, Cr, Ni, Pb, and Zn in placentas correlates 
with response of biomarkers metallothioneins, delta-amniolevulinic acid dehydratase, and 
lipid peroxidation [27]. Consistent with environmental exposure to these elements, both 
97 
 
 
levels of metals and biomarker responses were statistically significantly related to 
maternal dietary habits, consumption of canned food and bottled mineral water, as well as 
smoking [27]. Similarly, animal models have shown pregnant C57BL6/J mice 
administered sodium arsenite in drinking water result in dose-dependent accumulation in 
newborn pups [28]. Trace metals elicit pleiotropic biochemical and physiological effects 
such as mimicry of binding in protein active sites, oxidative changes in lipid, proteins or 
DNA, impaired transfer of nutrients to the fetus, low birth weight and developmental 
delay. The variation of chemical properties and reactive toxicities of each indicates that a 
uniform mechanism of action for all toxic metals is unlikely.  
Recent reports have demonstrated trace quantities of metals directly promote overall 
histone production, specific epigenetic modifications, and heritable changes in gene 
expression [29]. Most importantly, these changes have been shown to occur in stem cells, 
potentially being transgenerational. Dimethylation of H3 has been demonstrated to lead 
to gene silencing, and multiple metal exposures have been linked to this phenomenon. Zn 
can modulate overall histone gene expression and possibly mediate Zn effects on 
chromatin regulation [30]. Treatment of human mononuclear THP-1 cells with 50 
µmol/L ZnSO4 for 40 hours produced decrease of H2B transcription by 1.58 fold. 
Conversely, Zn deprivation by treatment with 2.5 µmol/L of the membrane permeable Zn 
chelator TPEN led to a 4.38-fold increase in H2B transcription. Exposure to Cd, Cr, Hg, 
and Ni leads to global changes in DNA methylation and histone modifications [29]. Ni 
ion exposure at 250 µM or higher increased global H3K9me and H3K9me2 by 2-3 fold in 
a time-dependent manner in cell lines of different lineages including mouse embryonic 
stem cells, human lung carcinoma cells, human osteosarcoma cells, human embryonic 
kidney cells, and mouse embryo fibroblast cells [31]. Further, Ni ions induced gpt 
transgene silencing and exhibited inhibition of H3K9 de-methylation, that led to, or 
permitted, the observed increase in H3K9me2 [31]. Acute in vitro exposure of mouse 
embryonic stem cells to As, Cd, Hg and Ni led to a more than 50% decrease in H3K27 
monomethylation (H3K27me) suggesting a global induction of transcriptional repression 
[32]. Low concentrations of trace metals also induce multiple cellular effects. Prolonged 
in vitro exposure of mouse embryonic stem cells to low concentrations (< IC50) of As, Cd, 
Cu, Pb, Li, Hg and Ni led to decreased cell proliferation, altered expression of cell 
differentiation markers Oct-4 and egfr, altered expression of DNA repair proteins Rad-18, 
Top-3a, and Ogg-1, and overall decreased total histone protein production [32].  
As a downstream result of transcriptional silencing by alterations in epigenetic marks, 
exposure leads to defects in cellular differentiation pathways. The As derivative arsenite 
suppresses expression of cellular differentiation markers to inhibit signaling pathways, 
maintain proliferative ability, and suppress differentiation of keratinocyte progenitor cells 
as well as transform human prostate epithelial progenitor cells to a cancer stem-cell 
phenotype [33-36]. In one study, SCC9 human squamous carcinoma cells that exhibit a 
keratinocyte progenitor cell phenotype were stably transfected with constructs containing 
the proximal human involucrin promoter, wild-type or mutated at both AP1 sites, were 
examined for their transcriptional activity using luciferase reporter activities with and 
without treatment with arsenate. Notably, effects were detectable with a nontoxic 
concentration within the range of environmental exposures (2 µM sodium arsenate or 
sodium arsenite). As one marker of inhibition of differentiation, arsenite resulted in a 
significant reduction of c-Fos transcription factor and of acetylated H3 at the proximal 
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and distal AP1 response elements of the involucrin gene promoter and of coactivator 
p300 at the proximal element of the involucrin gene promoter, as shown by chromatin 
immunoprecipitation (chIP) studies. Treatment with arsenite led to a dramatic 
suppression in the transcriptional activity of the involucrin gene to 2% of the level 
observed in the absence of any treatment.  
Studies have extended cell culture studies to examine long-term impact in vivo. Exposure 
of C57Bl6/J mice to 100 μg/L arsenic in drinking water from 1 week before conception 
until birth resulted in offspring with global H3K9 hypoacetylation, changes in functional 
annotation with highly significant representation of Krüppel associated box transcription 
factors in brain samples, and long-term memory impairment as compared to unexposed 
controls [37]. Timed-pregnant Long–Evans hooded rats exposed to 200 ppm Pb-acetate 
in deionized drinking water during pregnancy delivered offspring with age-related 
neuropathological characteristics analogous to those seen in Alzheimer’s disease (AD). 
These characteristics were accompanied by changes in the methylation patterns of key 
AD genes [38]. Continued exposure to Pb during the postnatal period resulted in a 
transient increase in beta-amyloid precursor protein (APP). mRNA expression during the 
first month after birth followed by a return to basal levels by 1 year, but suprisingly a 
subsequent delayed overexpression at 20 months after exposure to Pb had ceased. These 
data suggest that environmental influences occurring during brain development 
predetermined methylation patterns, gene expression, and regulation of APP later in life, 
potentially altering the course of amyloidogenesis. These studies support the fetal basis of 
adult disease (FeBAD) hypothesis which states that many adult diseases have a fetal 
origin [39-43]. Injury or environmental influences occurring at critical periods of organ 
development in the fetus at early stages of cell differentiation could lead to alterations in 
gene expression or gene imprinting which can result in "programmatic" changes in gene 
expression and functional deficits evident later in life. 
Epidemiological studies have well documented metals as human carcinogens associated 
with skin, lung, liver, and bladder cancers; however the underlying mechanisms have not 
been clear. Cancer incidence increases with chronic exposure to metals such as As, Cd, 
Cr, and Ni [44-47]. Studies associate arsenic exposure to multiple cancer types in human 
subjects and gene-specific DNA hypermethylation [48-52]. This direct link between 
arsenic, tumorigenesis, and hypermethylation was further documented by low dose (0.5 
μM) exposure to arsenic trioxide (As(2)O(3)) that led to transformation of BALB/c 3T3 
cells, and dramatic tumor growth increase of these cells in a xenograft mouse model [53]. 
Further, these cells exhibited activated polycomb group proteins BMI1 and SUZ12, 
increased H3K27me3, and suppression of p16 and p19 that could be rescued by shRNA 
to either BMI1 or SUZ12 [53].  
 
2.4 Bisphenol A and other estrogens  
 
Bisphenol A (BPA) is a hormonally active environmental xenoestrogen widely used in 
the production of polycarbonate plastics and resins, including some dental composites. 
Exposure to bisphenol A occurs through its use in food and drink packaging, and water 
pipes. Estrogens are both natural hormones produced in the body and widely used in 
hormone supplement therapy. 17β-estradiol is an endogenous estrogen. Genistein is a soy 
phytoestrogen present in foods. Genistein and other estrogen derivatives are also 
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available at health food stores as dietary supplements. The epigenetically toxic effects of 
environmental chemicals like BPA and phthalates include DNA methylation, histone 
modification, and changes in microRNA expression levels [2]. Some of these effects have 
been found to be transgenerational.  
Numerous studies show that exposure to xenoestrogens can developmentally reprogram 
multiple organ systems. Differences in the ability of xenoestrogens to induce 
developmental reprogramming are likely driven by intrinsic differences in their binding 
to specific estrogen receptoer subtypes. In the female reproductive tract, exposure is 
associated with alterations in morphology, hormonal response, and gene expression, and 
promote diverse outcomes such as obesity and cancer later in life [54-56]. BPA is an 
endocrine disruptor causing an adverse effect on mammalian reproduction due to 
impaired development of germ cells. BPA has been reported to play a role in modulating 
germ cell differentiation, retinoic acid signaling, and the expression of germ cell marker 
genes in mouse embryonic stem (ES) cells [57]. After 50 µM BPA, up-regulation of 
meiotic entry gene Stra8 (20-fold), up-regulation of ovarian markers Foxl2 and Wnt4 
(15-20 fold), and suppression of testicular markers Sox9 and Fgf9 were detected showing 
that in addition to germ cell differentiation, BPA also affects testicular and ovarian 
development. BPA dosing C57BL/6J pregnant mice from embryonic day 8.5 to 13.5 
accelerated neurogenesis in the developing neurocortex [58]. The number of neural 
stem/progenitor cells was decreased due to promotion of neurogenesis in the dorsal 
telencephalon. Animal studies have also reported that postnatal exposure to BPA 
accelerates neurogenesis and causes neuronal migration defects which impair neocortex 
development in embryos [59]. BPA modulates adipogenic differentiation of cultured 
human primary adult stem cells [60] and suppresses adipogenic differentiation of mouse 
mesenchymal stem cells [61]. 
Physiologically relevant doses of BPA or estradiol have been reported to increase 
susceptibility to adult-onset prostate precancerous lesions and hormonal carcinogenesis. 
This imprinting involves epigenetic changes such as permanent alterations in the DNA 
methylation patterns of multiple cell signaling genes [62]. Developmental exposure to 
estradiol and BPA leads to an increase in the susceptibility to prostate carcinogenesis 
with aging through epigenetic regulation [62]. In normal prostates, gradual methylation 
occurs within the specific genomic cluster containing the gene for phosphodiesterase type 
4 variant 4 (PDE4D4) which is an enzyme responsible for cyclic AMP breakdown. This 
methylation is associated with decreased expression. By contrast, neonatal Sprague-
Dawley rat exposure to BPA (10 µg/kg) or 17β-estradiol 3-benzoate (2500 µg/kg or 0.1 
µg/kg) resulted in early and prolonged hypomethylation at this site and continued, 
elevated PDE4D4 gene expression throughout life, consistent with observed 
hypomethylation of this gene in prostate cancer cells. Several genes showed methylation 
changes in response to neonatal estrogen treatments, many of which are permanent. 
Estrogens have also been linked to the generation of DNA DSBs or inhibition of their repair. 
Exposure of primary gingival fibroblasts to dental adhesives containing BPA derivatives 
produced increased numbers of DNA breaks, marking of damaged chromosomes with 
H2AX, alterations in cell cycle profiles, and slower kinetics of repair [63-65]. 
Sensitivity to BPA derivatives may be global as exposure of keritinocytes, skin 
fibroblasts, intestinal cells (line LS174T), and hepatoma cells (line HepG2) all produce 
marking of damaged DNA by H2AX [66, 67]. 
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3. Anti-cancer agents anthracyclins:  daunomycin 
 
Anthracyclins are powerful chemotherapeutic agents for the treatment of many cancers. 
Daunomycin has side effects of bone marrow suppression, anemia, and premature aging 
of the ovary. Histone acetylation increases the binding affinity of daunomycin by 
chromatin and enhances the DNA dissociation from nucleosomes possibly facilitating its 
effects through both DAN damage and suppression of transcription of active gene loci 
[68]. In multipotent hematopoietic cells (MHCs) of mouse bone marrow [69] 
daunomycin produces dose-dependent cell toxicity in parallel with time and dose-
dependent decrease in the amount of histone proteins bound to the DNA, and a decrease 
in methylation and acetylation patterns of histone H3 (H3K9ac and H3K9me2). These 
modifications cause compaction and aggregation of chromatin in MHCs of mouse bone 
marrow and transcriptional silencing. Mouse models indicate that while doxorubicin 
leads to DNA breaks, accumulating γH2AX foci, and cell death in the majority of 
primordial follicles, oocytes, and granulosa cell, a minor proportion of oocytes and 
granulosa cells survive that may result in long-term impaired function [70]. 
 
4. Inhibitors of Topoisomerase II  
 
4.1 Anti cancer agents 
 
DNA topoisomerases are essential cellular enzymes that cause topological changes in the 
DNA for processes such as replication and transcription. Topoisomerase II (topoII α and 
topoII β in mammalian cells[71]) is targeted and inhibited by the anti-cancer agents 
etoposide, doxorubicin, daunorubicin and mitoxantrone [71, 72]. These compounds 
inhibit the religation of the transient DSBs made by topo II potentially leading to 
illegitimate repair and chromosomal abnormalities.  
The induction of DSBs by topo II inhibitors is associated with chromosomal 
rearrangements, especially of the MLL gene that is frequently rearranged in therapy-
related leukemia following initial therapy to a primary tumor with agents such as 
etoposide. Etoposide has been reported to initiate MLL rearrangements in mouse 
embryonic stem cells [73], primitive hematopoietic stem cells and in human fetal 
hematopoietic stem cells in several studies [74-77]. Other anti-cancer agents including 
teniposide, anthracyclines and dactinomycin also are associated with MLL 
rearrangements due to topo II inhibition and enhanced DNA cleavage leading to defective 
DNA repair and chromosomal translocations [78]. 
 
4.2 Bioflavonoids 
 
Bioflavonoids comprise a diverse group of polyphenolic compounds. The most common 
sources of these bioflavonoids are fruits, vegetables, soy, tea, coffee and wine [79]. 
Genistein is abundant in soybeans. Due to their antioxidant capacity, they are used for 
their presumed health benefits such as protection against cardiovascular diseases, cancer 
and inflammation. Flavonoid supplements are available worldwide over-the-counter in 
pharmacies and drugstores.  
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However, accumulating evidence indicates that the dietary flavonoids are potent topo II 
inhibitors and induce DNA cleavage (i.e. DSBs), genome instability and chromosomal 
translocations. Topo II inhibition by bioflavonoids was investigated in an in vitro plasmid 
DNA cleavage assay using purified recombinant wild-type human topo IIα and IIβ where 
it was shown that these compounds were active against topoisomerase Iiβ [80]. Genistein 
(50 µM) was shown to be the most effective of the bioflavonoids tested and stimulated 
enzyme-mediated DNA cleavage ~10-fold [80]. It was shown that 100 µM genistein 
efficiently induced topo II-DNA cleavage complexes in both cultured mouse myeloid 
progenitor cells (32Dc13) and Top2β knockout mouse embryonic fibroblasts (MEFs), 
and it was suggested that these complexes are processed by proteasome which led to 
chromosome rearrangements [81]. Cultured human lymphocytes treated with 50 µM 
genistein display chromosome abnormalities in metaphase karyotypic analyses [82]. 
DSBs with the MLL gene breakpoint cluster region were induced by bioflavonoid 
exposure both in primary human progenitor hematopoietic cells from healthy newborns 
and adults as well as in hematopoietic progenitor cell lines (BV173 and K562) [83]. 
Quercetin, genistein and kaempferol induced DSBs in primary human hematopoietic 
CD34+ stem cell-enriched cells (at 25 µM and 50 µM doses) [84]. Besides chromosomal 
translocations, monosomy or trisomy of MLL was also reported in quercetin-exposed 
cells [84].  
Importantly, synthetic flavonoids are able to cross the placenta in the rat and are found in 
all fetal tissues (17% of the initial dose) including fetal brain [85]. Maternal and fetal 
distributions of a synthetic radioactively labeled bioflavonoid EMD-49209 were 
detectable 1-24 h after intravenous injection into pregnant Wistar rats. Transplacental 
exposure to high but biological amounts of the flavonoids genistein and quercetin in Atm-
ΔSRI mutant mice with an impaired capacity for DSB repair led to the Inverse PCR 
detection of two-fold higher number of MLL rearrangements compared with their wild-
type siblings [79]. Parallel in vitro studies with bone marrow cells exposed to genistein 
(50 µM) or quercetin (50 µM) showed 2.1-5 rearrangements/80ng genomic DNA (1 per 
13,000 cells) for quercetin or genistein as compared to 0.2 translocations/80 ng genomic 
DNA for wild-type cells. Thus, the risk of these rearrangements due to in utero exposure 
to these bioflavonoids increases in the presence of compromised DNA repair, although in 
this study MLL rearrangements were detectable in all samples regardless of diet or 
mutational status.  
The epigenetic and transgenerational effects of these dietary compounds were addressed 
in a study [86] which showed that the phytoestrogen genistein, a naturally occurring 
bioflavonoid, which is found in soy products leaves a permanent signature on the 
hematopoietic lineage. Studies have shown that exposure of progeny to genistein through 
maternal diet during pregnancy can have long lasting effects on the progeny. Mice 
(129/SvJ:C57BL/6J background), ~8 wk of age were given genistein (270 mg/kg of feed) 
from conception until birth. Genistein induced epigenetic changes and altered the coat 
color of agouti mice. In this study it was shown that mice prenatally exposed to genistein 
had a significantly increased hematopoiesis. It led to hypermethylation of repetitive 
elements and a significant down-regulation of genes involved in hematopoiesis in bone 
marrow cells of mice that were exposed to genistein. Thus prenatal exposure to genistein 
affected the process of DNA methylation of hematopoietic cells and caused long lasting 
alterations in gene expression while also affecting fetal erythropoiesis. 
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Exposure to the flavonoid quercetin during pregnancy can result in the long-term changes 
in iron homeostasis at adulthood [87]. Quercetin is a strong iron chelator and has the 
ability to cross the placenta and accumulate in the fetus. In this study female mice 
(129/SvJ:C57BL/6J background) were given quercetin (302 mg/kg feed) from 3 days 
before conception until the end of gestation. Mice prenatally exposed to quercetin had an 
upregulated iron-associated cytokine expression and significantly increased iron storage 
in the liver (~94 ng/mg for quercetin exposure versus ~62 ng/mg for control). Quercetin 
exposure was associated with hypermethylation of repetitive elements and these 
epigenetic modifications could cause these long-term changes in cytokine gene 
expression. All of these changes led to a shift towards a higher expression of cytokines 
associated with inflammation in the liver of adult mice that were prenatally exposed to 
quercetin.  
Quercetin has also been shown to affect xenobiotic metabolism of chemical carcinogens 
in mice that were prenatally exposed to this compound [88]. Mice (129/SvJ:C57BL/6J 
background) were given quercetin (1 mmol or 302 mg/kg of feed) from 3 days before 
conception until the end of gestation. Quercetin-exposed mice showed altered 
biotransformation of the environmental pollutant benzo[a]pyrene. This occurred due to 
altered gene expression of the metabolic enzymes such as Cyp1a1, Cyb1b1, Nqo1 and 
Ugt1a6 which persisted into adulthood in a tissue- and gender-dependent manner. These 
long lasting changes were associated with epigenetic alterations since prenatal quercetin 
exposure led to hypomethylation of repetitive elements SINEB1. These persistent 
alterations in the metabolic enzymes of adult mice may affect cancer risk due to 
environmental chemical carcinogens. 
 
4.3 Other drugs and pesticides  
 
Given the association of MLL gene rearrangements and translocations with both therapy-
related leukemias as well as infant acute leukemias, analysis of the MLL gene structure 
following exposure to multiple compounds has been widely studied in hopes of 
determining the common etiologies of these two diseases. Use of certain drugs and 
pesticides has also been reported to be associated with MLL gene fusions. A pilot case-
control study [89] that investigated the risk of infant acute leukemia due to transplacental 
chemical exposure reported that several groups of drugs including herbal medicines, the 
nonsteroidal anti-inflammatory drug, dipyrone and exposure to pesticides like 
mosquitocidals including Baygon were associated with MLL gene fusions across different 
countries and ethnic groups. MLL rearrangement status was derived by Southern blot 
analysis, and maternal exposure data were obtained by interviews using a structured 
questionnaire. 
Maternal use of dipyrone during pregnancy was shown to be associated with infant acute 
leukemia in a hospital-based case-control study conducted in different cities of Brazil 
[90]. A total of 202 children with newly diagnosed infant acute leukemia were enrolled 
along with 440 age-matched controls. The magnitude of the odds ratio of 1.45 for 
maternal exposure to dipyrone suggested the occurrence of interactions between dipyrone 
exposure during pregnancy and MLL rearrangements, leading to infant acute leukemia 
development. 
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5. Concluding remarks 
 
A growing body of evidence suggests that several environmental, dietary and therapeutic 
agents have the potential to cause long-term changes in multiple cellular functions. 
Epigenetic modulation, cell differentiation, gene expression, signal transduction and 
illegitimate DNA repair are all associated with human diseases and cancer [91]. The use 
of the environmental, dietary and therapeutic agents discussed above is widespread today. 
Evidence is emerging regarding the long-term implications and adverse effects of using 
these compounds in an unrestricted manner. Due to the beneficial effects assumed to be 
associated with the use of bioflavonoids, their use as dietary supplements is increasingly 
popular and widespread. In view of the variety of adverse effects these agents have in 
exposed individuals, it is important to raise public awareness, set guidelines and regulate 
the use and market availability of such compounds to reduce the risk of disease. Since the 
role of in utero exposures in causing long-term transgenerational effects has been 
demonstrated to be critical, it is important to address the susceptibility of different stages 
of cell differentiation to the deleterious molecular changes induced by these agents. 
However, a system to directly and rapidly examine the role of a large number of different 
compounds, both individually and in combination, in inducing the genetic/epigenetic 
changes discussed above has been lacking and thus testing has been limited to small 
isolated studies. Use of model systems for cells at different stages of differentiation with 
different susceptibility to genomic damage will provide useful insights into the 
comparative risk to the human population in terms of the different stages at which 
exposure occurs. 
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Abstract 
Infant acute leukemias account for approximately 30% of all malignancy seen in 
childhood across the Western world. They are aggressive and characterized by rapid 
onset shortly after birth. The majority of these have rearrangements involving the MLL 
gene, and AF9 is one of its most common fusion partners. Since MLL breakpoint 
sequences associated with infant acute leukemia are similar to those in secondary acute 
myeloid leukemia following exposure to the topoisomerase II poison etoposide, it has 
been hypothesized that exposure during pregnancy to biochemically similar compounds 
may promote infant acute leukemia. Hundreds of unregulated nutritional supplements are 
widely available and perceived to prevent cardiovascular disease, inflammation and 
cancer. However, there is epidemiological association between bioflavonoids in the 
generation of specific infant leukemias and multiple bioflavonoid compounds have been 
shown to inhibit topoisomerase II activity and promote DNA cleavage and MLL 
rearrangements. Thus, their potential to promote leukemic translocations should be 
directly determined. For this, we established a mouse embryonic stem cell approach to 
examine the potential for a large number of compounds to mediate DNA damage and 
repair that results in chromosomal translocations. We found that topo II inhibitors such as 
the bioflavonoids genistein, quercetin, luteolin and myricetin lead to MLL-AF9 bcr 
translocations, genistein and quercetin being the most potent promoters. By contrast, 
benzoquinone and dipyrone act through a different mechanism and do not generate GFP+ 
colonies in a statistically significant frequency. In addition, these results demonstrate that 
the identified MLL and AF9 breakpoint cluster regions are sensitive to these agents and 
recombinogenic independent of chromosomal context. This system now provides for 
rapid screening of hundreds of compounds, their systematic analysis of relative risk, dose 
dependence, and combinatorial impact. 
